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ARID proteins are highly conserved among eukaryotes and are involved in 
chromatin remodeling, differentiation and development.  The founding member of the 
ARID3 subfamily, Bright/ARID3A, is an activator of the immunoglobulin heavy chain 
locus. Bright has been shown to immortalize mouse embryonic fibroblasts and induce 
malignant transformation when co-expressed with oncogenic Ras. A genomic locus that 
encodes a gene paralogous to Bright has been identified as Brightlike/ARID3C.  In 
addition to the highly conserved ARID and REKLES domains, Brightlike contains a 
conserved sumoylation motif.  Brightlike orthologous genes have been identified in all 
vertebrate genomes examined.  Its absence from EST databases suggested that it is a rare 
transcript, and accordingly, its expression in adult mice appears to be restricted to spleen, 
testes and thymus.  Brightlike is also regulated by alternative pre-mRNA splicing, 
differential subcellular distribution, and post-translational modification by SUMO.  The 
two isoforms of Brightlike appear to have differential expression in lymphocyte 
populations.  Brightlike and Bright bind to the same DNA motif.  Unexpectedly, Bright 
 vii 
and Brightlike do not form heterocomplexes on DNA nor compete for binding, 
suggesting they have independent functions in vivo.  Brightlike increases the proliferation 
potential of mouse embryonic fibroblasts and rescues cells from premature senescence, 
suggestive of a proto-oncogene.  
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CHAPTER 1.  INTRODUCTION  
Background 
1.1 INTRODUCTION TO THE VERTEBRATE IMMUNE SYSTEM 
All Organisms, even bacteria, have evolved ways to fight pathogens, although a 
more sophisticated system evolved around the time of vertebrates (reviewed in Pancer 
and Cooper 2006).  Simply put, the vertebrate immune system adapts to the ever 
changing pathogens that infect the host and has the ability to recognize previously 
encountered antigens.  This is referred to as adaptive or acquired immunity, as opposed to 
the innate immunity all metazoans possess.  In order to work properly, the immune 
system has to distinguish self from non-self (reviewed in Kyewski and Klein 2006).   An 
immunological response is induced to foreign antigens while maintaining tolerance to 
host antigens.  Sometimes the pathogen escapes detection and can cause disease.  Failure 
in immune system self recognition (or self-tolerance) may result in autoimmune 
disorders, such as diabetes type I, Lupus, asthma and allergies (reviewed in Umetsu and 
DeKruyff 2006 and Fernando et al. 2008).  Crippling diseases such as Multiple Sclerosis 
can develop (reviewed in Hafler et al. 2005).  There seems to be a very fine line between 
initiation of an immune attack or protection and immune tolerance.  The vertebrate 
immune system is complex, and we have not begun to elucidate all the pathways 
involved.  Discovering new pathways and genes involved in cells specific to the immune 
system will help us unravel this intricate system. 
The fundamental goal of adaptive immunity is the generation of a large number of 
diverse receptors that have great specificity and high affinity against pathogens.  
Lymphocytes are cells that possess receptors specific for antigen binding.  Generally 
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speaking, the lymphocyte population involved in acquired immunity is composed of B 
and T cells.  Lymphocyte receptors are composed of variable (V), joining (J), diversity 
(D) and constant (C) regions (reviewed in Jung et al. 2006).  The V, D, and J genomic 
segments recombine during a process called VDJ recombination to form the diverse 
repertoire of T and B cell receptors.   Insertion or removal of nucleotides at the junctions 
of these recombined segments, as well as somatic hypermutation with them, adds to the 
receptor diversity (reviewed in Maizels 2005).  Consequently as many as 10^18 different 
T-cell and B-cell receptors can be made by less then 200 genes, with the intent to bind 
and inactivate pathogens in a highly specific manner (reviewed in Bowen and Corcoran 
2008).  Many T-cell specific and B-cell specific transcription factors and other proteins 
have been identified that are required for T cell receptors and immunoglobulins (Ig) to 
rearrange during T and B cell development, respectively (Janeway et al. 2001).  However 
the some of the major components of the recombination machinery and other systems are 
found in both. 
T cells 
The T cell differentiates in the thymus where it undergoes VDJ recombination to 
make a diverse array of T cell receptors (TCR) able to recognize millions of antigens.  T 
cells that express both CD4 and CD8 co-receptors and are referred to as double positive T 
cells (reviewed in Ellmeier et al. 1999).  Double-positive (DP) T cells undergo selection 
in the thymus before becoming single positive (SP) effector T cells, expressing either 
CD4 or CD8.  Double-positive T cells go through a process of negative and positive 
selection.  T cells can only recognize antigen presented by a major histocompatibility 
complex (MHC) molecule on the surface of antigen presenting cells (reviewed in van der 
Merwe 2003).  If a newly created T-cell receptor recognizes the MHC presented antigen 
too strongly it undergoes negative selection, resulting in apoptosis in order to prevent 
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autoimmune reactions.  Likewise, if the TCR recognizes the MHC-antigen complex too 
weakly it fails to be activated and is also negatively selected.  T cells that have an 
intermediate affinity for the MHC complex are positively selected and become single 
positive, mature thymocytes.  Mature single positive T cells are released from the thymus 
and enter the periphery.  CD8 single positive T cells, also known as cytotoxic T cells, are 
capable of inducing death to virally infected cells or to tumor cells (reviewed in Schepers 
et al. 2005).  Generally CD4 positive T cells are known as helper T cells because they 
assist B cells or macrophages destroy pathogens instead of directly killing infected cells 
as cytotoxic T cells do.  There are some exceptions to this, as there have been reports of 
other T cell types expressing CD4 (Curotto de Lafaille and Lafaille 2002).   
B cells 
B cell development originates in the bone marrow where VDJ rearrangement 
produces a cell surface receptor able to interact with antigen (reviewed in Melchers et al. 
2000). This stage of development is independent of antigen.  Cells strongly stimulated by 
nearby stromal cells are negatively selected.  B-cell antigen receptors are cell surface 
immunoglobulins.  Unlike T cells which recognize antigen presented by MHC molecules 
B cell receptors recognize antigens directly.  Only if the B cell encounters antigen in the 
periphery will they survive and proliferate.  Activated B cells can undergo further 
receptor diversification by somatic hypermutation or class switch recombination 
(reviewed in Teng and Papavasiliou 2007).  These activated B cells can become antibody 
secreting plasma cells or memory B cells.  Plasma cells secrete antibodies, or soluble 
immunoglobulins, that are specific to the encountered antigen.  Immunoglobulins are 
composed of two types of proteins:  heavy and light chains.  Two heavy and two light 
chains are stabilized by disulfide bonds to make their functionally relevant structure 
(Janeway et al. 2001).  Both heavy and light chains have variable (VH or VL) and constant 
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(CH or CL) regions.  There are five main classes of immunoglobulins (IgM, IgD, IgG, IgE 
and IgA) which are distinguished by the constant region of their heavy chain.  All B cells 
initially express IgM on their surface.  After stimulation by antigen they can differentiate 
into plasma cells secreting IgM or can undergo isotope switching to express other 
isotypes on their surface prior to differentiating into plasma cells that secrete the new 
isotype.  IgD is coexpressed on mature B cells with IgM through an alternative 
splicing/alternative polyadenylation mechanism.  IgD is secreted in small amounts and its 
function remains unclear.   
B-cell receptor genes 
The highly complex heavy chain (IgH) locus is located on chromosome 12 in 
mice and 14 in humans.  The murine locus spans a region of about 3 Mb containing 8 
constant genes (C), 4 joining genes (J), 10-13 diversity genes (D) and about 150 variable 
genes (V). V segments have been divided into ~15 different families based on sequence 
homology (Chevillard et al. 2002, de Bono et al. 2004, Ye 2004, and Mainville et al. 
1996).  It is thought that most V gene segments undergo VDJ recombination but they 
may not encode receptors that mediate survival of B-cell progenitors into mature B cells.  
There have been notable differences of variable gene usage in different mouse strains.   
Each variable gene has its own promoter and 5’ regulatory region.  Many of the 
variable genes have TATA-related sequences and/or Inr elements (Johnston et al. 2006).  
Many V gene promoters contain the octameric sequence ATGCAAAT shown to be 
necessary but not sufficient for V gene transcription (Eaton and Calame 1987).    Most 
families, including the S107 family (described in more detail below), also contain 
additional conserved upstream elements (eg, Pu1 binding sites) (Johnston et al. 2006).  
Binding sites for matrix attachment region (MAR) binding proteins are relatively 
abundant (discussed in more detail below).  Binding sites for the Bright transcription 
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factor (discussed in more detail below) are present in 41 of 110 sequences in non-
conserved areas between -250 and -500, with the exception of the J558A subfamily 
which contains Bright binding sites at -475 (Goebel et al. 2002).  The IgH V gene locus 
also contains non-V genes, but because their locations are not conserved across species, 
their significance is unknown (Matsuda et al. 1998).   There are also regulatory regions 
downstream of the variable region, including the intronic enhancer (Eµ) which is 
positioned between the J segment and Cµ region.  IgH rearrangement juxtaposes the 
VDJ-associated promoters and Eµ into proximity (Banerji et al. 1983). 
The human Igh V region locus spans an ~1 Mb region of chromosome 14 
(Johnston et al. 2006).  It contains 123 V genes. However, only 44 have been shown to be 
functional.  This differs from the murine locus which has more (110) functional genes 
then pseudogenes (85).  The octamer sequence is highly conserved within all human 
variable gene promoters.  Within families, the distance between the TATA box and 
octamer is also conserved.   
The S107 gene family 
The murine S107 V1 (T15) immunoglobulin gene segment is the VH gene used in 
the response to phosphorylcholine (PC) expressed on the capsule of bacteria such as 
Streptococcus pneumoniae (Malipiero et al.1987).  This VH gene has been implicated in 
anti-DNA autoimmunity (Diamond and Scharff 1984) and in Lupus-prone mice 
(Trepicchio and Barrett 1987).  It is believed that anti-PC antibodies are capable of 
converting to anti-DNA antibodies by somatic hypermutation (Diamond and Scharff 
1984, Pewzner-Jung et al. 1996, Wun et al. 2001).  More specifically, Diamond and 
Scharff (YEAR) examined the reactivity of antibodies derived by somatic mutation in the 
S107 myeloma cell line. S107 produces a PC binding IgA antibody that is identical in its 
VH sequence to the T15 (V1) germ line heavy chain V (Crews et al. 1981). It was 
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previously reported that a somatic mutant of S107, U4, produced an antibody that had 
lost the ability to bind PC, due to a single amino acid substitution of an alanine for a 
glutamic acid at residue 35 in the CDR1 (Rudikoff et al. 1982).  Diamond and Scharff 
(YEAR) showed that this U4 mutant alternatively binds to double stranded DNA.  These 
results demonstrated that an antibacterial antibody coding germ line V region gene can 
loose the ability to bind to the bacterial antigen and attain the ability to bind to self as the 
result of somatic mutation in the heavy chain V region.   
MARs and the Nuclear Matrix  
The nuclear matrix, sometimes referred to as interchromatin space, has been 
defined as the proteinatious material that remains after high salt extraction of DNase1-
digested nuclei (reviewed in Scheuermann and Garrard 1999).  MARs were isolated as 
DNA sequences that bind in vitro to isolated nuclear matrix.  MARs are greater then 70% 
A + T rich regions, at least 250 bp long, and occur in genomes every 10 to 100 kb.  It has 
been suggested that replication, repair, recombination and transcription may be organized 
by the nuclear matrix since a number proteins essential to these processes associate with 
the nuclear matrix in vitro and in vivo (Scheuermann and Garrard 1999, Davie 1997, and 
Roch et al. 1997).  Attachment of DNA to the nuclear matrix via MAR sequences and 
interaction with MAR-binding proteins have been shown to alter chromatin by organizing 
its conformation into transcriptionally active domains, promoting histone acetylation and 
regulating demethylation (Davie 1997).  MARs have also been implicated in somatic 
hypermutation, VDJ recombination—a process dependent on localized changes in 
chromatin structure—and enhancer function of the immunoglobulin genes.  MARs have 
been identified in the Ig κ  light chain, the IgH chain gene locus (specifically Eµ, CH, and 
5’ of several VH promoters), the T cell receptor (TCR) β  gene and α /δ  gene loci, and the α δδ
TCR co-receptor CD8 gene locus (Scheuermann and Garrard 1999 and Glazko et al. 
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2003).  MARs may contribute to Ig transcription by juxtaposing promoter and enhancer 
elements within common nuclear matrix domains (Scheuermann and Garrard 1999 and 
Davie 1997).   Bf150 and Tx125 discussed subsequently are MAR regions located 
upstream of S107 VH1 (Webb et al. 1991). 
 
1.2 ARID PROTEINS  
ARID (AT-Rich Interaction Domain)-containing proteins are highly conserved 
among eukaryotes (reviewed in Kortschack et al. 2000).  Founding members were 
originally identified as proteins that bound to A-T rich DNA in vitro (Herrscher et al. 
1995, Gregory et al. 1996).  The ARID DNA binding domain consists of about 80 amino 
acids which form a helix-turn-helix structure that binds to the major grove of DNA 
(Iwahara et al. 2002, Kim et al. 2004).  Characterized ARID members include mouse 
Bright, human modulator recognition factors MRF-1 and MRF-2, Drosohilia 
melanogaster Dead ringer (DRI), Saccharomyces cerevisiae SWI1 and its human and 
Drosophila homologs, p270 and osa, respectively, jumonji, SmcX, SmcY, and 
retinoblastoma-binding proteins, RBP1 and RBP2.  Mammalian ARID proteins and their 
proposed functions and tissue specificity can be found in Figure 1.  ARID members are 
thought to participate in lineage decisions, cell cycle control, tumor suppression, and/or 
modulation of chromatin (Wilsker et al. 2002).  They display 84%-90% conservation in 
their ARID domains (Patsialou et al. 2005).  ARID-containing proteins are found in a 
broad array of organisms from fungi to mammals.  Their presence in fungi indicates that 
this domain arose early in eukaryotic evolution (Kortschack et al. 2000). 
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ARID3 Sub-family 
Mammalian ARID proteins are subgrouped into 7 different ARID families.  
Bright (B cell regulator of IgH transcription) and Bdp (Bright-Dri-like protein), are 
members of the eARID3 subgroup.  Bright/ARID3A and Bdp/ARID3B share extended 
(e) identity beyond their ARID DNA binding domain (Fig. 2c).  Bright and Bdp contain a 
second shared domain, the self-association/protein interaction domain, REKLES, termed 
for a hexapeptide within the motif that is conserved among orthologues (Kim et al. 2007, 
Kortschack et al. 2000). Sequence alignment suggested that the REKLES domain could 
be divided into two sub-domains: a modestly conserved N-terminal REKLES α  and a 
highly conserved 20 amino acid C-terminal REKLES β  (Fig. 2c) (Kortschack et al. 2000).  
REKLES α  and REKLESβ  are required for the nuclear import and eβ xport of Bright, 
respectively (Kim and Tucker 2006).  REKLES β  has also been identified as a region 
necessary for both homo- and heteromeric eARID interactions (Kim et al. 2007). 
ARID3A (Bright) 
Bright is a MAR-binding protein that transactivates gene expression from the 
immunoglobulin heavy chain (IgH) locus intronic enhancer (Eµ) (Herrscher et al 1995).  
It was first discovered in a mature murine B-cell line, BCg3R1-d, as a mobility shifted 
complex that increased µ mRNA levels in response to IL-5 and T-cell dependent 
stimulation (Webb et al. 1991).  Bright binds to the A+T rich MAR regions of the 
intronic heavy-chain enhancer and some VH promoters, including the V1 S107 gene 
family.  It is believed that Bright regulates chromatin accessibility for V gene 
recombination (Goebel et al. 2002).  Preliminary studies have indicated that in embryonic 
mice, Bright mRNA can be detected in numerous developing organs (L Allred, personal 
communication).  Conventional disruption of the Bright gene results in early (E11.5) 
embryonic death (L Allred, personal communication).  Adult expression appears more 
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limited, with expression being restricted to certain stages of B cell development (Webb et 
al. 1998).  Bright has been shown to immortalize primary fibroblasts and rescue primary 
fibroblasts from natural senescence or Ras-induced senescence (Peeper et al. 2002).   
Bright is a matrix associating region (MAR)-binding protein that transactivates 
gene expression from the immunoglobulin heavy chain (IgH) locus intronic enhancer 
(Eµ) (Herrscher et al 1995).  It was first discovered in a mature murine B-cell line, 
BCg3R1-d, as a mobility shifted complex that increased µ mRNA levels in response to 
IL-5 and T-cell dependent stimulation (Webb et al. 1991).  Bright binds to the A+T rich 
MAR regions of the intronic heavy-chain enhancer and some VH promoters including the 
V1 S107 gene family.  It is believed that Bright regulates chromatin accessibility for V 
gene recombination (Goebel et al. 2002).  In embryonic mice, Bright mRNA can be 
detected in numerous developing organs.  Conventional disruption of Bright results in 
embryonic death.  Adult expression appears more limited, with expression being 
restricted to certain stages of B cell development (Webb et al. 1998).  Bight is expressed 
in detectable amounts in pre-B cells and in late stages of B-cell differentiation, but not in 
immature B cells, suggesting it is not needed for maintaining Ig expression.  Bright has 
been shown to immortalize primary fibroblasts and rescue primary fibroblasts from 
natural senescence or Ras-induced senescence (Peeper et al. 2002).   
A considerable amount of Bright resides in the cytoplasm of normal and 
transformed B cells (Kim and Tucker 2006). Leptomycin B inhibition, chromosome 
region maintenance 1 (CRM1) over expression, and heterokaryon fusion experiments 
suggest that Bright shuttles between the nucleus and the cytoplasm in a CRM1-dependent 
manner.  The nuclear localization signal (NLS) was mapped to the N-terminal region of 
REKLES, and residues within the C-terminus of REKLES contain its nuclear export 
signal (NES). In support of Bright’s role in the cell cycle, growth factor depletion and 
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cell synchronization experiments indicated that Bright shuttles during S phase of the cell 
cycle, leading to an elevated nuclear/cytoplasmic ratio which decreased as the cells 
entered G2/M phase. In addition shuttle-incompetent Bright point mutants, even if 
sequestered within the nucleus, are incapable of transactivating an IgH reporter gene. 
Consequently, regulation of Bright's cellular localization appears to be required for its 
transcriptional function and may be involved in its potential role in the cell cycle (Kim 
and Tucker 2006). 
Recently Dr. Carol Webb has created transgenic mice that overexpress Bright in 
all B cell lineages (Shankar et al. 2007).  These mice fail to maintain B cell tolerance, 
produce anti-nuclear antibodies and undergo spontaneous autoimmunity.  An increase in 
splenic immature transitional B cells (both in total cell numbers and in comparison to 
other B cell fractions) was found in transgenic mice compared to littermate controls.  This 
stage in B cell development is an established B-cell tolerance checkpoint in the spleen 
(reviewed in Yurasov et al. 2005).  Serum Ig levels, particularly IgG isotypes, were also 
increased in the Bright-transgenic mice compared with littermate controls.  T15 
antibodies, which utlize the V1 gene segment, had increased expression.  One year old 
mice showed IgG deposits in the kidney glomeruli—a feature of autoimmunity. These 
findings implicate Bright overexpression in B cell autoreactivity or failure to maintain B-
cell tolerance. Thus, Bright is the first B cell-restricted transcription factor demonstrated 
to induce autoimmunity.  There also appears to be an upregulation of Bright in the 
peripheral blood of Lupus patients as compared to healthy controls (personal 
communication, CF Webb).   
ARID3B (Bdp) 
In comparison to Bright, less is known about Bdp.  Bdp, a ubiquitously expressed 
protein, was identified by GST pulldown as a putative tumor suppressor that interacts 
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with retinoblastoma protein (Rb) (Numata et al. 1999).  In contrast to Bright, Bdp resides 
exclusively in the nucleus.  Bdp also binds to the MARs of the IgH locus, and its ability 
to form heteromeric complexes with Bright via their REKLES domains suggests that 
these proteins may work in conjunction to transactivate gene expression from the IgH 
locus (Kim et al, 2007).  Recent publications (Kobayashi et al. 2006 and Takabe et al. 
2006) suggest Bdp is involved in neural crest development. Its aberrant expression plays 
a role in neuroblastoma progression.  Bdp null mice show early embryonic lethality, and 
this may be associated with abnormal development of chranial mesenchymal cells. 
 
1.3 POST-TRANSLATIONAL MODIFICATION BY SUMO 
Post-translational protein modification is a fundamental and multipurpose system 
that has been implicated in regulatory activity, stability, subcellular localization, protein-
protein interaction and/or DNA binding ability of its substrates (Hilgarth et al. 2004).  
Proteomic analysis has identified a number of SUMO (Small Ubiquitin-like Modifier) 
substrates (reviewed in Hay 2005 and Dohmen 2004).  Most of these substrates are 
involved in chromatin organization, transcription, and RNA metabolism (reviewed in 
Hay 2005, Dohmen 2004 and Gill 2004).  Assembly of transcription factors at promoter 
regions is important in controlling gene expression.  Transcription factors subsequently 
recruit a series of proteins involved in chromatin remodeling and posttranslational 
modification of histones.  Sumoylation has been shown to be involved in the assembly of 
transcription factors and recruitment of chromatin remodeling enzymes (reviewed in Gill 
2005).  Rarely, SUMO modification of transcription factors leads to transactivation; 
mostly it is involved in transcriptional repression (reviewed in Gill 2005).  This is often 
associated with their relocation to NBs (reviewed in Gill 2003 and Gill 2005).  Other data 
suggest that sumoylation regulates nuclear cytoplasmic transport (reviewed in Hay 2005).  
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Currently there are two models to explain SUMO-related transcriptional repression: (1) 
either SUMO-modified transcription factors alter chromatin structure by recruiting co-
repressor molecules or (2) SUMO-modified factors are better suited to recruitment into 
the repressive environment of subnuclear domains.  Both models have evidence to 
support them, and it appears that the mechanism depends on the substrate (reviewed in 
Gill 2005).  Some data suggest a higher sumoylation rate in proliferating cells (reviewed 
in Hay 2005) consistent with decreased transcription during cell division.  SUMO is 
targeted to proteins by the same enzymatic process as ubiquitin, utilizing an activating 
enzyme, E1 (dimer of SAE1 and SAE2), and conjugating enzyme, E2 (Ubc9), and in 
some cases a ligase, E3 (reviewed in Hay 2005, Dohmen 2004 and Gill 2004).  Several 
E3s have been identified by their ability to increase the efficiency of sumoylation.  
Sumoylation of proteins is dynamic, and can be reversed by sumo-specific isopeptidases 
(reviewed in Hay 2005 and Dohmen 2004).  In a yeast two-hybrid library screen, Bright 
strongly interacted with Sp100, UBC9 (SUMO E2), and PIAS1 (SUMO E3).  Bright, 
Sp100 and PML are all modified by SUMO-1.  The sumoylated forms of PML and Sp100 
show specific nuclear localization to nuclear bodies (NBs) (reviewed in Dohmen 2004).  
Reciprocally, PML sumoylation mutants do not form NBs (Zhong et al. 2000).   
 
1.4 CELLULAR SENESCENCE 
In order to avoid aberrant cell proliferation, cells become quiescent, senescent or 
undergo apoptosis.  Senescence was first described by Hayflick and Moorhead in human 
fibroblasts in 1961.  It has been referred to as the ‘Hayflick phenomenon’ in honor of Dr. 
Leonard Hayflick.  It was hypothesized that senescence was essential to limit the lifespan 
of cells.  This would be helpful in terms of damage by oxidative stress, DNA damage, or 
other destabilizing events.  Senescent cells in culture are large in size, flat, and are unable 
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to synthesize DNA.  Dimri and colleagues observed the presence of β -galatosidase in 
senescent cells in culture.  Using a colorimetric assay with X-gal at pH 6.0, senescent 
cells can be distinguished from proliferating or quiescent cells (Dimri et al. 1995).  
Senescence is believed to occur naturally when telomeres shorten and induce a DNA 
damage response.  This is often referred to as intrinsic senescence.  Aside from DNA 
damage, other stress factors can trigger a senescent like phenotype.  It is believed that 
murine cells in culture undergo senescence because of stress induced by culture 
conditions.  It has been shown that oncogenic and mitogenic signals, such as activated H-
RAS, can also induce senescence in primary cells.  Senescence induced by nontelomeric 
signals is referred to as extrinsic or premature senescence.  Regardless of the signals that 
initiate senescence many tumor suppressor pathways have been show to be critical in 
senescence initiation and maintenance.  Specifically, p53, PML, and pRB have all been 
shown to regulate senescence.  p53 has been shown to impede cell proliferation by G1 
and G2 cycle arrest, senescence or apoptosis.  Studies suggest that p53 induces 
senescence by p21-dependent Cyclin E and D inactivation.  Cyclin inactivation keeps 
pRB in a hypophosphorylated which is observed during cell cycle arrest.  Loss of pRB is 
sufficient for cell cycle entry and reversal of senescence.  PML is upregulated during 
senescence, and its overexpression can induce premature senescence.  These studies and 
others suggest that senescence may function to prevent tumorigenesis (reviewed in Dimri 
2005).  There is still some controversy as to whether senescence is an in vitro 
phenomenon.  Nonetheless, experiments involving senescence have provided insight into 
important pathways involving proto-oncogenes and tumor suppressor genes.   
Support for a physiologically relevant role of senescence has become more 
accepted with recent in vivo studies.  It is generally believed that senescence plays a role 
in aging.  Senescent cells have been shown to secrete degradative enzymes and cytokines. 
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This finding can explain how telomere shortening leads to age-related tissue pathology 
(Hampel et al. 2006, Xu et al. 2008).  In addition, senescent cells were identified in aging 
human skin (Dimri et al. 1995) and liver (Paradis et al. 2001).   One in vivo study showed 
that E2F, which induces a hyperproliferative signal, induced a senescence phenotype in 
murine pituitary glands.  It is also commonly believed that senescence may be a 
mechanism for inhibiting the progression of tumors.  Senescence markers have been 
identified in several in vivo lesions including human melanocytic nevi (Michaloglou et 
al. 2005, Gray-Schopfer et al. 2006) and dermal neurofibromas (Courtois-Cox et al. 
2006), murine lung adenomas (Dankort et al. 2007), pancreatic intraductal neoplasias 
(Collado et al. 2005), melanomas (Ha et al. 2007) and lymphomas (Braig et al. 2005) and 
human and murine prostatic adenomas (Chen et al. 2005).  Furthermore, senescence may 
contribute to the efficacy of some cancer chemotherapy drugs (Schmitt et al. 2002, te 
Poele et al. 2002).   
Activated RAS (V12) was found to induce premature senescence in primary cells.  
This cell cycle arrest resembles normal senescence in terms of associated acidic β -
galactosidase expression.  Tumor suppressor deficiency or expression of oncogenes can 
bypass RAS-induced senescence and can facilitate transformation (Serrano et al. 1997).  
Weinberg and Hahn (2002) demonstrated that, in order to create an in vitro model of 
cancer, one must initially abrogate senescence.   A current model suggests that failure of 
senescence-inducing pathways in addition to activation of oncogenes, leads to tumor 
formation in vivo.  Combinination of the simian virus large T antigen (SV40 large T), 
small t, or hTERT, with H-RAS transforms a number of human cell types.  Bypassing 
senescence is also essential for murine cell transformation.  SV40 large T alone is 
sufficient to abrogate senescence in both murine and human cells (reviewed in Dimri 
2005).   
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Benards group developed an unbiased screen to identify novel genes that bypass 
RAS-induced senescence.  Using conditionally immortalized RAS expressing fibroblasts 
with a temperature sensitive large T antigen and a retroviral cDNA library, they found 
that RAS-induced senescence was abrogated by oncogenes such as human Bright 
(hDril1) and BCL6, by indirectly by-passing the pRb and p53 pathways, respectively 
(Peeper et al. 2002 and Shvarts et al. 2002).  The cDNA library that resulted in four 
independent clones of BCL6 was generated from peripheral blood lymphocytes of a 
patient suffering from polycythaemia vera, a myeloproliferative disorder (Shvarts et al. 
2002). The human Bright clone was isolated from a JEG3 human chorion carcinoma cell 
cDNA library (Peeper et al. 2002).  It was then shown that human Bright targets the pRb 
pathway by activating E2F1 (Peeper et al. 2002). We have shown that Bright bypasses 
senescence through the accumulation of CYCLIN E, regulated by hyperphosphorylated 
pRb, and activation of E2F1 (C. Schmidt, D. Kim, L Probst, unpublished data). This 
suggests that Bright-overexpressing cells are released from senescence and enter S phase.  
E2F1 activation may be a consequent of pRb sequestration, as Bright can form an 
immunoprecipitable complex with pRb.  Consistent with this, Bdp was originally cloned 
in a yeast two hybrid screen for pRb interacting partners (Numata et al. 1999), and as 
mentioned above, has also been associated with a role in transformation (Kobayashi et al 
2006).  pRb binding proteins, RBP1 and RBP2, also belong to the ARID family (Wilsker 
et al. 2002).  Taken together, the results suggest that ARID member participate in cell 
fate as components of the Rb pathway.  Bright is expressed in germinal centers, where 
mature B cells proliferate rapidly during late stages of differentiation.  That this process 
is regulated by E2F1, G1 Cyclins, and pRb phosphorylation may connect Bright’s normal 
function with its ability to bypass premature senescence.   
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Initial Goals and Hypotheses 
EXAMINE THE EXPRESSION OF BRIGHTLIKE/ARID3C 
 We identified a genomic locus that appeared to encode a gene paralogous to 
Bright and Bdp.  We first called it Brightlike.  However, more recent nomenclature has 
designated it as ARID3C.  The lack of Brightlike ESTs, led us to hypothesize that 
Brightlike/ARID3C is tightly regulated, perhaps accumulating at low levels in tissue-
restricted subsets of cells or after an environmental cue.  In order to establish a function 
for Brightlike/ARID3C it was necessary to first examine its expression pattern.  RT-PCR, 
Nothern blot analysis, in situ hybridization, immunohistochemistry, and Western blotting 
can all give insight into expression.  Since we assumed that the message would be in low 
levels, RT-PCR seemed to be the most appropriate approach because of its sensitivity.  
The first approach was to design nested PCR primers which would utilize two rounds of 
PCR.  Outer primers would amplify a region of Brightlike, but this may still not be 
detectable.  However, that outer reaction could be used as a template for an inner PCR 
reaction that may be visible by gel electrophoresis.  Another approach would be to 
perform (what we refer to as) “virtual” Northern--essentially a Southern blot of RT-PCR 
products using a gene-specific probe.   Subcellular localization would also be examined.  
We expected that Brightlike would localize to both the cytoplasm and nucleus, as it 
shares high amino acid sequence similarity with the regions in the REKLES domain 
determined to be the nuclear export and import sequences of Bright.  Bdp does not have 
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the sequence shown to be necessary for export, and accordingly, is localized to the 
nucleus.   
 The lack of ESTs could be explained by a low RNA levels, but perhaps the 
protein would be more stable.  Therefore, we produced an anti-Brightlike anti-sera that 
would be useful in Brightlike protein detection.  This anti-sera could be used for Western 
blot analysis or immunohistochemistry; both would be attempted.  The antibody would 
also be useful in other assays, such as super-shifting potential Brightlike/DNA 
complexes, in co- or chromatin-immunoprecipitation analyses. 
 
INVESTIGATE THE DNA BINDING PROPERTIES OF BRIGHTLIKE 
The presence of the highly conserved ARID domain suggested that Brightlike 
may recognize and bind to the same IgH-associated MARs as Bright and Bdp.  Electron 
mobility shift assays (EMSAs) would be utilized to examine if Brightlike binds to the 
same DNA probes as Bright and Bdp.  A point mutation in Bright creates a dominant 
negative form of Bright that is unable to bind to DNA.  This same mutation would be 
created in Brightlike to further investigate its specificity for this region.  Chromatin 
immunoprecipitation (ChIP) would be utilized to confirm in vivo binding.  These assays 
might provide insight into molecular pathways regulated by Brightlike. 
 
DETERMINE IF BRIGHTLIKE INTERACTS WITH OTHER ARID3 MEMBERS VIA ITS 
REKLES DOMAIN 
 We have previously shown that Bright interacts with itself and with Bdp and this 
is dependent on the REKLES β  domain.  We have also shown that this interaction was 
necessary for DNA binding (Kim et al. 2007).  Co-immunoprecipitation would be utilized 
to investigate if Brightlike also interacts with other ARID3 members via its REKLES 
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domain.  Mutations in this region that disrupt possible protein-protein interaction would 
further support this hypothesis.  These mutations could also be used in EMSAs and we 
expect them to be unable to bind to the same probes as Bright.  If Brightlike interacts 
with Bright/Bdp, ChIP could be used to determine if they interact in DNA bound 
complexes. 
 
EXAMINE THE ABILITY OF BRIGHTLIKE TO TRANSACTIVATE THE HEAVY CHAIN 
LOCUS 
 In mature mouse B cell lines, Bright was identified as a mobility shifted complex 
that correlated with increased heavy chain levels in response to interleukin-5 and antigen 
(Webb et al. 1991).  When cells are transfected with Bright, Btk, TFII-I and the S107 
heavy chain reporter, Ig transcription in enhanced (Rajaiya et al. 2006).  NIH 3T3 cells 
that have been stably transfected with a V1 S107 heavy chain promoter upstream of 
luciferase and transient transfection of Brightlike and/or Bright, Btk and TFII-I would 
provide insight as to whether Brightlike regulates transcription from the S107 heavy 
chain promoter. 
 
TEST THE ABILITY OF BRIGHTLIKE TO RESCUE CELLS FROM PREMATURE 
SENESCENCE 
 ARID3A has been shown to rescue cells from premature senescence, and both 
ARID3 members have been shown to transform primary cells when co-expressed with a 
known oncogene (Peeper et al. 2002 and Kobayashi et al. 2006).  Therefore, it seemed 
feasible to determine if Brightlike could also rescue cells from senescence.  Expression of 
two ARID3s in combination may even be sufficient to transform primary cells.  If 
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Brightlike rescued cells from senescence, the mechanism of senescence rescue could be 
examined.  This might also give insight into pathways regulated by Brightlike.   
 
DETERMINE BIOLOGICAL CONSEQUENCES OF SUMO MODIFICATION 
 Brightlike contains a sumoylation consensus sequence at lysine residue 284. A 
point mutation at this reside (K284R) should disrupt this modification.   Post-translational 
modifications often have an effect on protein function.  Sumoylation has been shown to 
be involved in protein subcellular localization.  It has often been linked to sub-
compartments within the nucleus, such as nuclear bodies, the nuclear periphery and the 
nuclear pore complex.  Many transcription factors appear to be inhibited by sumoylation, 
and this is often associated with this change in localization.  Brightlike and its putative 
sumoylation mutant, Brightlike K284R, would be tested in the transcription assays 
described in the previous section.  A reasonable prediction would be that SUMO-I 
modification of Brightlike would decrease its transactivation activity. Perhaps 
sumoylated Brightlike would localize to NBs or to the nuclear periphery, whereas 
unmodified Brightlike would be more centrally localized.   
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Figure 1.  ARID family of DNA binding proteins.  Mammalian ARID proteins are 
involved in chromatin remodeling, transcriptional regulation, proliferation, development 
and tumorigenesis.  Some ARID proteins have broad expression across tissues and some 
have a more restricted expression (Patsialou et al. 2005 and http://www.ncbi.nlm.nih.gov)
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Figure 2. Relationships within the ARID3 family.  (A) Schematic of mouse ARID3 
genomic loci.  Brightlike (ARID3C) is compressed compared to Bright (ARID3A) and 
Bdp (ARID3B) (B) Schematic protein alignment of mouse ARID3 family showing 
domains and motifs shared.  (C)  Amino-acid alignment of mouse ARID3 conserved 
elements.   
A ARID3A- Bright 
ARID3B- Bdp 
ARID3C- Brightlike 
 
B 
C 
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CHAPTER 2.  MATERIALS AND METHODS 
COMPUTATIONAL ANALYSIS 
ARID3C was identified as an uncharacterized region on mouse chromosome 4 
and human chromosome 9 by comparison with Bright and Bdp coding sequences.  
Genomic sequences were obtained from Ensembl.org.  The National Center for 
Biotechnology Information (NCBI) web site (http://www.ncbi.nlm.nih.gov/) was used to 
compare (BLAST) sequences against the protein and nucleic acid databases.  Alignments 
were made using ClustalW.  All computation analysis was preformed by my colleague 
Loren Probst. 
 
CELL SORTING 
Double positive T cells were sorted using FITC -conjugated anti-CD4 and PE-
conjugated anti-CD8 (BD Pharmingen) by my colleague Jian Lin.  All remaining 
thymocytes were labeled as double negative, although other populations of cells 
remained.  Thymuses were taken from 5-6 weeks old C57BL/6 mice. Only sorted cells 
with higher than 99% purity were used in the experiment.  Single positive splenocytes 
were sorted by my colleague Hui Nie.  To collect CD4 and CD8 single positive 
splenocytes, pooled spleens from C57B/6 mice were magnetically separated by anti-
mouse CD4 (L3T4) MicroBeads, or anti-mouse-CD8a (Ly-2) MicroBeads according to 
the manufacturer’s instructions (Miltenyi Biotec Inc. Auburn, CA).  The resulting CD4 
and CD8 cell pellets were saved at -80 until used for RNA isolation.  CD43 positive cells 
were isolated from murine spleen using anti-CD43 MicroBeads according to 
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manufacturere’s protocol (Miltenyi Biotec Inc. Auburn, CA).  Unlableled cells were 
collected as CD43 negative cells.   
 
RNA ISOLATION 
Tissues or cells were either stored in RNA Later or directly added to Trizol 
reagent (GibcoBRL).  Tissues were homogenized by a polytron homogenizer.  Cells were 
lysed by pipetting.  RNA was isolated following Invitrogen’s Trizol protocol.  RNA was 
resuspended in DEPC water.  After removal of DNA contamination with DNase I for 1 
hour at 37°C, the reaction was terminated by adding EDTA (final concentration 2.5 mM) 
at 70°C for 10 minutes.  RNA concentration was determined by using a nanodrop 
spectrophotometer.   
 
CDNA SYNTHESIS 
SuperScript™ First-Strand Synthesis System for RT-PCR (Invitrogen) was used 
to make all cDNAs according to manufacturer’s protocol.  2-5ug of total RNA was used 
as template in a 20ul total reaction.  Oligo (dT) was used to synthesis all poly-A mRNA 
transcripts. 
 
PCR AMPLIFICATION 
 2 ul of cDNA was used for Brightlike PCR reactions and 1ul was used for tubulin 
reactions.  For full length amplification an outer PCR reaction was performed using 5’ 
and 3’ UTR primers ~50 nucleotides upstream of the start site and stop codon.  The UTR 
reaction was used as a template for the full length open reading frame amplification.  Full 
length primers amplified the open reading frame.  All primers used and information 
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regarding them can be found in Appendix A.  Taq polymerase (NEB or Gene Choice) 
was used with the provided reagents following manufacturer’s protocol.  Tubulin was 
used as a positive control in every PCR reaction using cDNA.   
 
VIRTUAL NORTHERN 
 PCR reactions or T-cell cDNA was run on at 1% agarose gel.  Ethidium bromide 
was removed by washing 20 minutes in warm water.  The gel was denatured in 
denaturation solution (0.5N NaOH, 1.5M NaCl) for 1 hour then neutralized in 
neutralizing solution (1.5M NaCl, 1M Tris pH 7.5) for 1 hour.  The DNA was transferred 
to a N+ Hybond nitrocellulose membrane (Amersham) overnight in 20X SCC (3 M 
NaCl, 0.3 M sodium citrate, ph 7).   DNA was crosslinked with UV light.  The membrane 
was incubated at 42°C with pre-hybridization solution or ULTRAhyb™ (Ambion) for 2 
hours.  Oligonucleotides were end-labeled with γ -ATP32 by polynucleotide kinase (New 
England Biolabs) for 1 hour at 37°C.  The probe was purfied using Microspin 6 columns 
by centrifugation at 3500 rpms.   CMP were counted by (BioScan/QC2000) and 107 
CMPs were added to the pre-hybridization solution and incubated at 42°C overnight.  
The membrane was washed 2X for 2 hours with 3X SSC plus 0.01% SDS or 2X 5 
minutes with 2X SSC, 0.1% SDS and 2X 15 minutes of 0.1% SSC, 0.1% SDS at 42°C.  
The membrane was then wrapped in Saran wrap and exposed to a phosphoimager 
cassette for 2 hours or overnight and analyzed by a phosphorimager (Molecular 
Dynamics)..    
 
EXPRESSION CONSTRUCTS 
Brightlike, Brightlike∆ 66, their putative sumoylation mutans, or their putative DNA 
binding mutants were subcloned into PCR3.1 (Invitrogen) and/or pEGFP-C1 (GenBank).  
Brightlike was PCR amplified with Bgl II flankng primers and cloned into pGEM-t Easy 
(Promega).  The fragment was digested and gel purified and ligated into the BamH I site 
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of pE-GFP-C1, disrupting both Bgl II and BamH I sites.  Digestion with Kpn I was used 
to determine proper orientation.  5’ Sal I and 3’ Not I primers were used to amplify 
Brightlike from pEGFP-C1 and ligated into PCR3.1-HA-Bcl11xs (given by colleague Dr. 
Gregory C. Ippolito) cut with Sal I and Not I.  DNA sequencing was used to verify all 
constructs using the dye termination method (UT sequencing core).  BTK and TFII-I 
expression plasmids were a gift from Dr. Carol Webb. 
 
PLASMID PREPARATIONS 
 Plasmid constructs were prepped by Qiagen or Invtrogen minprep kits according 
to manufacturer’s protocol.  DNA was eluted using ddH2O warmed to 70˚C.  
Concentrations were obtained using a nanodrop spectrophotometer.   
 
MUTATION REACTIONS 
 Stratagene’s mutation protocol for the QuikChange II Site-Directed Mutagenesis 
kit was used to introduce putative sumoylation or DNA binding mutations into pGEM T-
easy vectors (Invitrogen) containing Brightlike or Brightlike∆ 6.  However we used our 6.  However we used our 
own reagents for this standard PCR-based mutagenesis.  Phusion DNA polymerase was 
used with an extension temperature of 72°C for 1 minute/Kb.  Pfu HF buffer was used 
(Stratagene).  10 ng of template was used in the reaction and 125 ng of each Y197A 
mutant oligonucleotide or 200ng of SumoK1mutb.  Oligonucleotide sequences can be 
found in Appendix A.  Primers were annealed at 55°C for 30 seconds.  16 cycles were 
used for the DNA binding mutation reaction and 18 cycles were used for the sumoylation 
mutation reaction.  DNA sequencing by dye termination method (UT sequencing core) 
was used to confirm the mutations. 
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GFP FUSION PROTEIN SUBCELLULAR LOCALIZATION STUDIES 
pEGFP-C1 Brightlike constructs were transiently transfected into 293T or 
NIH3T3 cells grown in either 100mm plates containing coverslips or in 4 well chamber 
slides.  Cells were fed 24 hours post transfection.  Images were acquired 48 hours post 
transfection.  Cells were mounted with Vectashield mounting media (Vector) containing 
Hoescht dye (final concentration 1ug/ml) to stain the nucleus.  Images were collected 
using an Olympus IX-70 inverted microscope, equipped with a 100 watt HBO (mercury) 
illuminator and a Diagnostic Instruments Spot RT-KE monochrome cooled CCD camera.   
 
ANTI-BRIGHTLIKE ANTIBODY PRODUCTION 
Anti-Brightlike polyclonal antisera was raised in New Zealand white rabbits 
against N-terminal (amino acids 4-100) or C-terminal (214-380) portions of Brightlike∆ 6, 6, 
selected because they lack significant homology to Bright or Bdp.  The N- and C-term 
sequences of Brightlike were cloned into the EcoR1 site of the GST vector pGEX6p1.  
The fusion proteins were expressed and purified from E. coli, and following 3 
immunizations, rabbits were sacrificed and sera collected.  Anti-Brightlike sera was 
tested on 3T3 cells transfected with the Brightlike GFP expression construct. 
 
IN VITRO TRANSLATION 
T7 or T3 RNA polymerase was used to synthesize PCR3.1 HA Brightlike or 
Bright protein, respectively, using Promega’s TNT® Quick Coupled 
Transcription/Translation System according to manufacturer’s protocol.  The translation 
reaction was always incubated at 32°C for 2 hours instead of the recommended 30°C.  
 27 
250ng of PCR3.1-HA Brightlike or Bright constructs were used as a template for the in 
vitro translation reactions with a total volume of 12.5ul (1/4 of recommended amount) or 
1ug in a total volume of 50ul.   
 
CELL LINES 
Cell lines were incubated at 37˚C and maintained in an atmosphere of 5% CO2 
except for BTR cells which were grown at 32˚C or 39.5˚C.  Adherent cells were cultured 
in DMEM (GibcoBRL/Invitrogen) supplemented with 10% fetal calf serum (PAA 
Laboratories), 1mM L-glutamine, 1% non-essential amino acids (GibcoBRL/Invtrogen). 
Non-adherent cells were cultured in RPMI-1640 (GibcoBRL/Invitrogen) supplemented 
with, 2 mM L-glutamine, and 10% fetal calf serum.  293T cells were a gift from Dr. 
Robert Krug (UT Austin).  Pheonix cells were provided by Arthur L. Shaffer at the NIH.  
NIH 3T3 and Cos-7 cells were obtained from ATCC.  BTR cells were a gift from Dr. 
Daniel Peeper (Netherlands Cancer Institute).  MEFs were isolated from day 12 mouse 
embryos as previously described (Bradley 1987) by my colleague Shan Maika.  Cells 
were generally split every 3-4 days.  AB1.2 hybridoma cells expressing the S107 V1 gene 
were selected with HAT (hypozanthene) for fusion (thymadine kinase -) versus myloma 
cells.  Bcg3R-1d cells were suplimented with 0.1 µg/ml mycophenolic acid.  Jurkat cells 
were supplemented with 25mM Hepes.   
 
WESTERN BLOT ANALYSIS 
Cell lysates were made using RIPA buffer (150mM NaCl, 50 mM Tris pH 7.4, 
0.1% SDS, 1% Triton X-100, 1% Deoxycholate, 1 mM EDTA) supplemented with 
protease inhibitors (Roche), incubated on ice for 30 minutes then cleared by 
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centrifugation at 3000 RPM.  Bradford (Bio-rad) reagent was used to determine protein 
concentration of cell lysates.  10 or 12% SDS-PAGE gels were used to separate proteins 
from cell lysates.  6X SDS loading buffer (300mM Tris, 10% glycerol, 6% SDS, 0.03% 
bromophenol blue, pH adjusted to 6.8, 30% β -mercapthoethanol) was added to samples 
and then boiled for 5 minutes before loading proteins into wells.  Proteins were 
transferred to a nitrocellulose membrane (PROTRAN®) using a standard semi-dry 
transfer apparatus.  Membranes were blocked with 5% milk in PBS-T (150mM NaCl, 
10mM Tris pH 8, 0.1% Tween-20) at room temperature for 2 hours or overnight at 4˚C 
with agitation.  Membranes were incubated with primary antibody for 3 hrs at room 
temperature or overnight at 4˚C with agitation.  Membranes were washed twice for 5 
minutes and once for 15 minutes with PBS-T (150mM NaCl, 10mM Tris pH  8, 0.05% 
Tween-20).  Membranes were incubated with secondary antibody for 1 hour at room 
temperature and washed with PBS-T as described above.  Blots were developed using 
ECL Western blotting detection reagent (Amersham Pharmacia Biotech) according to the 
manufacture’s instructions.  The following dilutions were used for each antibody:  HA-
1:1000, Brightlike- 1:1000, Bright 1:5000, anti-GFP 1:5000, anti-mouse or anti-rabbit 
1:8000). 
 
LIPID RAFT ISOLATION 
On ice 300mg cells (~ 107 cells) were washed twice in PBS and then 2.7mL TNE 
was added to the pellet.  10X TNE can be made and kept at 4°C (100mM Tris; 2.0M 
NaCl; 10mM EDTA; pH 7.4).  Cells were disrupted with 15 strokes using a Dounce 
homogenator keeping cells on ice. Extracts were transferred to a micro-centrifuge tube, 
centrifuged at 3,000 rpm at 4°C, and then the pellet was discarded.  The supernatant was 
centrifuged at 100,000x g for one hour and the pellet was re-suspended in 450 µL 
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1xTNE-T (1xTNE containing 1% Triton X-100).  The pellet was sonicated in TNE-T for 
a few seconds.  A gradient was assembled as follows: 187.5 µL 60% sucrose + 125 µL 
TNE-T (312.5 µL ~ 40% solution), 437.5 µL 60% sucrose + 312.5ÂµL extract (750µL ~ 
30% solution) and 145 µL 60% sucrose + 1.6mL TNE-T (1.75mL ~5% solution). TNE-T 
may be substituted for extracts if needed.  Every solution was mixed in a 2 mL tube and 
the gradient was assembled first by adding 40% solution first, then 30% solution and then 
5% solution. Tubes were tared using a 5% solution and spin at 100,000x g for ~1 day. 
Rafts are visible between the 5% and the 30% interface and these fractions were isolated 
using a P200 pipettman.  Membranes are at the interface between 30% and 40% solution 
and may also be removed at this point.  Samples were concentrated using 
methanol/chloroform precipitation and solubilized in RIPA buffer.  Lipid raft 
preparations were then subject to Western blot analysis. 
 
IMMUNOFLUORESCENCE 
Cells were fixed using 4% paraformaldehyde at room temperature for 10 minutes, 
then permeablized with 0.5% Triton X-100 for 5 minutes. Cells were washed 2X with 
blocking buffer (PBS/5% BSA/0.01% Tween-20) for 10 min.  Primary antibodies diluted 
1:500 in blocking buffer were incubated for 30 minutes at room temperature.  Following 
primary incubation cells were washed 2X with PBS for 10 min.  Goat α -rabbit-Alexa red 
(Company) was also diluted 1:500 in blocking buffer and incubated for 30 minutes at 
room temperature in the dark then washed 2X with PBS for 10 min in the dark.  Cells 
were mounted using Vectasheild mounting media with Hoescht dye (final concentration 
1ug/ml) to stain the nucleus.   
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IMMUNOHISTOCHEMISTRY 
Paraffin embedded testes sections were a gift from Dr. Richburg’s lab.  Paraffin 
was removed by 3X 5 minute washes in Xylene (Fisher Chemicals).  Sections were 
rehydrated by incubating in 100% EtOH, followed by 95% EtOH and 70% EtOH, then in 
ddH2O for 5 minutes each.  Antigens were unmasked by incubating in 10mM Sodium 
Citrate for 30 minutes at 37˚C.  Endogenous peroxidase activity was quenched with 
peroxide block (ScyTek).  ScyTek’s EconoTek HRP (DAB) Anti-Polyvalent kit was used 
according to manufacturer’s protocol.  Sections were incubated in primary antibody 
overnight at 4˚C in a humidified chamber.   
 
CO-IMMUNOPRECIPITATION 
Sepharose A bead slurry was prepared by my colleague Chhaya Das.  Protein-A 
immobilized on Sepharose CL-4B (cat # P3391) was purchased from Sigma.  300 mg 
protein-A beads were washed in 10 ml of low IPB buffer (25mM Tris pH 7.5, 150mM 
NaCl, 2mM EDTA, 0.5% NP-40) with 1mg/ml BSA for at least an hour while rotating at 
room temperature or overnight at 4°C.  Beads were washed 2 times in 10 ml low IPB and 
resuspended in an equal volume of low IPB.   
293t cells were co-transfected with GFP-Bright or Empty GFP and PCR3.1, HA-
FLBL, HA-BL∆ 66, or HA-PSF in 100mm plates.  Cells were checked for GFP expression 
48hrs post transfection.  Standard whole cell lysate protocol was followed.  Lysates were 
pre-cleared with 50% Sepharose A bead slurry.  Fresh protease inhibitors (Roche) were 
added to theh 50% slurry before each use.  An aliquot of pre-cleared lysate was saved for 
input lanes.  Lysates were precipitated with α -Bright, α -Brightlike, or pre-immune serum.   
Primary antibody incubations were done over-night at 4°C with the addition of protease 
inhibitors (Roche) and 12 mM PMSF.  Beads were spun down at 3000 RPM and washed 
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with lysis buffer (50 mM HEPES-KOH, pH 7.4, 200 mM KCL, 10% glycerol, 1% NP-
40, 1 mM EDTA, 1 mM DTT) 3X 5 minutes.  The first 2 washes were supplemented with 
1% Trition-X.  Beads were resuspended in 30ul of 2X SDS sample buffer (100mM Tris, 
25% glycerol, 2% SDS, 0.01% bromophenol blue, pH adjusted to 6.8, 10% β -
mercapthoethanol) for loading 3 gels. 
 
ELECTRON MOBILITY SHIFT ASSAYS 
BF150 or TX125 probes were digested from 20-25 µg of the following plasmids 
constructed in our lab:  PUC-PCRIL5 or 251-125R by Hind III or EcoR I, respectively.  
The Erag enhancer used as a negative control was generated by PCR.  The PCR fragment 
(199 bp) corresponds with Region A of the RAG enhancer (Hu et al. 2006).  Digested or 
PCR products were labeled with γ -ATP32 using polynucleotide kinase (New England 
Biolabs) and gel purified from a 7% polyacrylamide gel.  The running buffer for the gel 
is 1X TBE (90 mM Tris-Borate, 2 mM EDTA).  Probe preparations were done by my 
colleague Chhaya Das.  In vitro translated Bright, Brightlike or putative DNA binding 
mutants were incubated with probes in a binding buffer for 30 minutes at room 
temperature (20mM HEPES pH 7.9, 40mM KCl, 6mM MgCl2, 1mM DTT, 0.1% NP40, 
3mg/ml BSA, 10% glycerol, 2% Ficoll, 50ug/ml of sonicated salmon sperm DNA and 
protease inhibitor cocktail (Roche)).  For super shift reactions anti-HA, anti-Bright or 
anti-Brightlike was added and incubated on ice for 30 minutes.  Pre-immune serum was 
used as a control.  Binding reactions were loaded onto a 4% polyacrylamide non-
denaturing gel (6% glycerol in 0.5X TBE) and run overnight at 4°C in 0.5X TBE running 
buffer.  Gels were dried and analyzed by a phosphorimager (Molecular Dynamics). 
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CHROMATIN IMMUNOPRECIPITATION (CHIP) 
 The ChIP was preformed by my colleague Chhaya Das using AB1.2 
hybridoma cells or Bcg3R-1d.  A saturated 40 ml culture using a p150 culture dish (0.5-
0.6 x 107 cells) was used per IP. The cells were pelleted by centrifugation, the media 
aspirated, and then resuspended in 20 ml of RPMI culture medium (5% FBS).  Cells were 
cross-linked by adding formaldehyde to a final concentration of 1%.  Formaldehyde was 
added directly to culture medium (540 µl added dropwise using a commercial stock 
solution of 37% HCHO/10% MetOH) and cellular chromatin was crosslinked at RT for 
either 10 minutes (“Chromatin #1” sample) or 20 minutes (“Chromatin #2” sample) with 
periodic rocking by hand. The reaction was terminated by immediately diluting with a 
maximal volume of ice-cold PBS (supplemented with Roche complete mini protease 
inhibitors plus PMSF)..  Cells were centrifuged 5 min and the solution then aspirated 
from the cellular pellet. Pellets were washed twice using ice-cold PBS (supplemented 
with Roche complete mini protease inhibitors plus PMSF).  Cells were then resuspended 
in 5 mls LYSIS BUFFER #1 (50 mM Tris-HCl, pH 8.0, 2 mM EDTA, pH 8.0, 0.1% 
Nonidet P-40, 10% Glycerol, Roche complete mini protease inhibitor “cocktail” should 
be freshly added 1 tablet into 10 mls) and lysed 5 min on ice. 2.5 mls were transferred to 
each of 2 microcentrifuge tubes, and spun @ 3,000 rpm (~ 2,700x g) @ 4°C for 5 min in 
a TOMY MTX-150 refrigerated microcentrifuge to pellet nuclei. The pelleted nuclei 
were resuspended in 2.0 ml LYSIS BUFFER #2 (50mM Tris-HCl, pH 8.0, 5mM EDTA, 
pH 8.0, 1.0% Lauryl Sulfate (SDS), Roche complete mini protease inhibitor “cocktail” 
should be freshly added 1 tablet into 10 ml) on ice for 10–20 min. The chromatin was 
then sonicated by a Branson 250 “Sonifier” soncicator (90% duty cycle, power setting = 
3) using 5 pulses of 15 sec each; the chromatin was incubated 1 min on ice between 
pulses. An aliquot was reverse crosslinked (65°C in the presence of 5M NaCl overnight) 
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and checked by gel electrophoresis to determine that the chromatin had been sheared to 
an average size of 200–1000 bp.  Chromatin supernatants were collected and spun @ 
13,000 rpm @ 4°C for 10 min in a TOMY MTX-150 refrigerated microcentrifuge, and 
the clarified supernatant was transferred to a new tube and then diluted 1:10 in IP buffer 
(0.1% SDS, 1% Triton X-100, 1.5 mM EDTA, 150 mM NaCl, 15 mM Tris-HCl pH 8.0, 
1x protease inhibitor cocktail, 10 mM NaF, 5 mM Na Butyrate) and were precleared by 
rocking on a platform with 2 µg sheared salmon DNA and protein A-sepharose (50% 
slurry in PBS + NaN3) overnight at 4°C.  The Chromatin was immunoprecipitated with 6 
µg per IP anti-Bright or anti-Brightlike or 6 µg preimmune rabbit IgG (Bethyl Labs 
P120-101) as control.  Immunoprecipitation was performed overnight at 4°C. After 
immunoprecipitation, bead-bound precipitates were washed 5 min sequentially with 
solutions TSE I (0.1% SDS, 1.0 % TRITON X-100, 2mM EDTA, pH 8.0, 50mM Tris-
HCl, pH 8.0, 150mM NaCl), TSE II (0.1% SDS, 1.0 % TRITON X-100, 2mM EDTA, 
pH 8.0, 50 mM Tris-HCl, pH 8.0, 500 mM NaCl), and LND (250mM LiCl, 1.0 % NP-40, 
1.0 % Deoxycholate, 1mM EDTA, pH 8.0, 10 mM Tris-HCl, pH 8.0), then three times 
with TE (10mM Tris-HCl, pH 8.0, 1mM EDTA, pH 8.0).  During the final wash with TE 
buffer, but before pelleting the protein A-sepharose beads, one-third of the beads were 
removed, spun down, resuspended and boiled in Laemmli loading solution, and run on a 
7.5% Western gel to confirm the successful pulldown of Bright. To elute the remaining 
two-thirds, 250 µl of freshly prepared elution buffer (1% SDS, 0.1 M NaHCO3) was 
added for 15 min @ RT on a platform rocker; the elution was repeated once more. 
Eluates were heated at 65°C (in the presence of 5M NaCl) for at least 6h to reverse the 
formaldehyde cross-linking. Chromatin was extracted once with phenol-chloroform, then 
once more with chloroform only.  A 2 µl aliquot (from  a total ~ 400 µl) was used for 
each PCR and the products were analyzed on a 2% agarose DNA gel after 40 cycles of 
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PCR using previously reported conditions (Rajaiya et al. 2006) or using an annealing 
temperature of 62°C with 72°C extensions of 30 sec each. PCR reactions were performed 
using the following primers: ChIP-F and ChIP-R (see Appendix A) originally named V1 
and Cµ (Rajaiya et al. 2006).   
 
TRANSIENT TRANSFECTIONS 
FuGENE6 (Roche) or Mirus (Mirus Bio Corporation) were used to transfect 
constructs into cells following manufacturer’s protocol.  4ug or 1ug of DNA was used to 
tranfect 100mm plate or 6 well plates, respectively.  DNA used was always prepped by 
Invitrogen’s Miniprep kit. 
 
LUCIFERASE ASSAY 
BTR cells (NIH 3T3 cells stably transfected with Bf150/TX125 upstream of 
luciferase) were plated at 1 x 105 cells per well in 6 well plates. 24 hours later, cells were 
transiently co-transfected with 375 ng of empty vector, Btk, TFII-I, Bright, and/or 
Brightlike constructs (for a total of 1.5 µg/well) and 5 ng of pRL luciferase construct 
(Promega) using Mirus transfection reagent ((Mirus Bio Corporation). The luciferase 
activity was measured 48 hours post-transfection by using Dual-luciferase Reporter 
Assay System (Promega) according to the manufacture’s instructions. Values were 
expressed as percent of those obtained using the basic reporter construct and regulatory 
element-containing reporter constructs after normalization of transfection efficiency with 
the activity of Renilla luciferase that is encoded in pRL vector. To evaluate the Brightlike 
effect, values were used as percent of values obtained using the reporter activities. 
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BTR ASSAY 
The BTR assay was performed as described previously (Peeper et al. 2002).  GFP 
Brightlike, Brightlike∆6, their putative sumoylation mutants, Bright or empty GFP were 
used to transfect BTR cells using Mirus (Mirus Bio Corporation) according to 
manufacturer’s protocol.   Transfection efficiency was determined by GFP expression.  
Cells were incubated at 32°C and duplicate plates were switched to 39.5°C after 8 hours 
post transfection.  β -galactosidase activity is a known characteristic of senescent cells not 
found in presenescent, quiescent or immortal cells (Demri et al. 1995).  After 10 days of 
culturing BTR cells transfected with Brightlike constructs β -Gal staining was performed 
as previously described (Demri et al.).  Cells were washed once with PBS, then fixed 
with 3% paraformaldehyde for 5 minutes at room temperature.  Cells were stained with 
X-gal solution (1mg/ml X-gal, 0.12mM K3Fe[CN]6. 0.12 mM K4Fe[CN]6, 2 mM 
MgCl2, 150 mM NaCl in PBS, pH6.0) overnight at 37°C.  Cells were counterstained with 
Eosin to stain the cytoplasm. 
 
SUMOYLATION CONSENSUS SEQUENCE.   
All ARID3 members were screened for a sumoylation consensus site using 
SUMOplot™ (http://www.abgent.com/doc/sumoplot).   
 
POTENTIAL EFFECT OF SUMOYLATION ON SUBCELLULAR LOCALIZATION.   
NIH3T3 cells were transiently transfected with GFP-Brightlike or its putive 
sumoylation (K284R) mutant or BTR cells, mouse embryonic fibroblasts transformed by 
SV40 tag, were transiently transfected with GFP fusion proteins of the two isoforms of 
Brightlike or their putative sumoylation (K284R) mutants.  Imaging of live cells was 
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performed by taking images every 10 minutes to generate a time lapse video of the GFP 
signal.  Images were collected using an Olympus IX-70 inverted microscope, equipped 
with a 100 watt HBO (mercury) illuminator and a Diagnostic Instruments Spot RT-KE 
monochrome cooled CCD camera.  Live cell time lapse photomicrography was 
performed in a 200 ml cylindrical PVC chamber infused with a 5% CO2/95% air gas 
mixture at a 75% relative humidity, and maintained at a 34C temperature on the 
microscope stage.  All images were captured as 1600x1200 8-bit greyscale .tif files.  Post 
capture image stack manipulation was performed using ImageJ v 1.   
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CHAPTER 3.  RESULTS 
3.1 GENOMIC IDENTIFICATION OF ARID3C 
3.1.1 IDENTIFICATION OF A NEW ARID3 PARALOG, ARID3C 
A genomic search led to the identification of a region that appears to encode a 
gene paralogous to Bright/ARID3A and Bdp/ARID3B, which we named 
Brightlike/ARID3C.  The genomic size of Brightlike is compressed compared to Bdp and 
Bright (6kb, as compared to 40-50 kb, respectively; Fig.2a).  The Bright and Bdp coding 
exons are conserved in length, for the most part, and most intron-exon junctions are 
conserved.  The identification of a REKLES-β  exon downstream from the ARID 
confirmed that it was a new ARID3 member.  Conservation within the predicted open 
reading frame suggested that Brightlike is a protein encoding gene.   
Unexpectedly, our initial inspection of metazoan EST databases revealed no 
Brightlike transcripts. Bright and Bdp are well represented.  More recently, Brightlike 
message was cloned from Gallus gallus (chicken) and from Sus scrofa (pig).  The 
absence of the message in EST databases suggested that it is rarely expressed, perhaps 
induced under rare environmental conditions or in a narrow subset of tissue.  Relying on 
conservation with the other ARID members (and also between mouse and human), 
Brightlike exon sequences were pieced together. The data were somewhat “soft” in 
several areas, until cDNA amplification (described below) confirmed its existence.  
Sequences were aligned using Clustal-W.  A sequence database search was performed 
using Blast.  Brightlike shares the eARID and REKLES domains as well as the SUMO 
conjugation consensus (Fig. 2b).  An orthologous gene has been identified in all 
vertebrates examined.   
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There is a unique region that is specific to lizard and mammalian ARID3C 
immediately to the N-terminal of the sumoylation site.  It appears that the chicken (Gg), 
the marsupial (Md) and the mammalian (Hs human, Mm mouse, Cf dog, Bt cow) show 
similar conservation through this region. This is unique to ARID3C and is not found in 
the fish or amphibian ARID3C orthologs. This suggests that the conserved element was 
fixed around 300 million years ago, and further strengthens the argument that the 
ARID3C genes of chicken and mammals are true orthologs. 
At both the N-terminus and C-terminus of the core of REKLES beta are 
sequences that are unique to ARID3C (GISSINM on the N-term and VLFARR on the C-
term).  These flanking sequences are again unique to ARID3C, with similar but not 
identical sequences being found in ARID3A and ARID3B.  This again suggests that the 
ARID3C genes are true orthologs, and this conservation extends to amphibian and fish 
(Xt, frog; Dr, zebrafish; Tn, pufferfish; Tr pufferfish).  The evidence supports the view 
that the ARID3C gene was created by duplication before the divergence of fish (400 
million years ago).  There are some regions where the ARID3C of Gg (chicken) shows 
greater similarity to ARID3A and ARID3B, but this is not unexpected.  The chicken and 
mammalian ARID3C genes have diverged for 300 million years, and so the mammalian 
has acquired some regions that have mutated and fixed during this time and which are 
therefore unique to the mammalian genes.  
 
3.1.2 ARID3C LOCUS 
The Brightlike gene is sandwiched on human chromosome 9 (9p13.3) between the 
dynactin 3 (2kb downstream) and opioid receptor sigma (13kb upstream).  These genes 
are each transcribed in the same direction.  Both of these genes are commonly expressed 
in a wide variety of tissues. Based on their numbers of human ESTs, they are expressed at 
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least 100 to 1000-fold more highly than Brightlike.  The 5' UTR is conserved in 
Brightlike down to fish.  The 3' UTR is less conserved, but it is still highly conserved 
within mammals.  Alignment of these regions are shown in Figure 5.  Notably there are a 
couple of regions of conservation, between the first and second ARID exons of 
Brightlike, within the intron.  The intronic conservation is somewhat unusual, and we 
expect that this might be involved in transcriptional control of the locus (another 
possibility would be control/stability of unspliced mRNA).  Since the length of the 5' and 
3' UTRs were not formally established, we designed primers just upstream and 
downstream of the open reading frame to perform the RT-PCR analyses described 
below.   
 
3.1.3 BRIGHTLIKE CONTAINS A SUMOYLATION CONSENSUS SEQUENCE 
Sequence alignment (Fig. 2c) of Brightlike and Bright suggested that K284 of 
Brightlike (orthologous to Bright K403, a known sumoylation site) is a putative SUMO 
conjugation site in Brightlike.  All ARID3 members were screened for sumoylation 
consensus sites using SUMOplot™ (http://www.abgent.com/doc/sumoplot).  Bright and 
Brightlike scored very high in the positions indicated on Fig. 6.  Bdp does not have a 
consensus sequence for sumoylation.  If Bdp proves not to be sumoylated, then SUMO 
modification may help to diversify the function of the paralogous members of this protein 
family.  In collaboration with Dr. Van Wilson at Texas A&M University, we determined 
that, in vitro, murine Bright is sumoylated at K403.  Brightlike contains the consensus 
motif ψ KxE (where ψ  is a large hydrophobic or aliphatic residue preferably L, I, or V and ψ
x is any residue).   
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3.2 Brightlike/ARID3C expression and cloning 
3.2.1 BRIGHTLIKE/ARID3C IS A BONA FIDE TRANSCRIPT IN MURINE SPLEEN.   
Total RNA from mouse spleen and subsequent cDNA synthesis were performed 
by RNAzol and Super Script II, respectively, according to manufacturer’s protocol.  We 
designed nested PCR primers that should amplify the low concentrations of RNA 
anticipated for this seemingly rare message.  Initially nested primers were designed to 
amplify Brightlike’s ARID domain (Fig. 7). Then nested primers were designed to 
amplify the entire open reading frame (discussed below; Fig. 8).  We observed bands of 
predicted sizes, suggesting that Brightlike was a bona fide transcript.  These PCR 
products were subcloned into Topo 2.1 with the Topo-TA cloining kit (Invitrogen) and 
sequenced.  Sequencing confirmed the PCR products were, indeed, the ARID region of 
Brightlike. 
 
3.2.2 TWO ISOFORMS OF BRIGHTLIKE/ARID3C ARE EXPRESSED IN MURINE TISSUES 
Brightlike was identified and cloned from mouse spleen, thymus and testes 
cDNA.  For full length amplification PCR, we used 5’ and 3’ UTR primers ~50 
nucleotides upstream of the translational start site and downstream of the stop codon.  
This was something of a gamble as a splice shortly upstream of the start or downstream 
of the stop, or a short UTR would have caused us a problem.  While these remain formal 
possibilities, we feel neither is probable..  In order to amplify the full length message 
using a nested primer approach, we were required to design the outer primers upstream 
and downstream to some extent.   
Using primers that amplified the open reading frame with the 5’ and 3’ primed 
PCR product as template, a product slightly smaller then the predicted size of Brightlike 
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was amplified.  The PCR product was cloned into Topo 2.1 with the Topo-TA cloning kit 
(Invitrogen) and the insert was sequenced by the dye termination method (UT sequencing 
core).  After cloning and sequencing, Brightlike was identified and confirmed as a 
cellular mRNA, albeit lacking part of the highly conserved protein-protein interaction 
(REKLES-β ; exon 6) domain.  We named this isoform Brightlike∆6.  The remaining 
transcript was identical to the predicted with the exception of a single nucleotide change 
(C/A) at position 786.  This transversion did not result in an amino acid change.  Based 
on the exon/intron boundaries (Fig. 3), all murine full=length clones initially isolated 
corresponded to an alternatively spliced form that excluded exon 6—the region that 
encodes the REKLES-β  domain (Fig. 3).  We have shown that this domain is necessary 
for homo and heteromeric ARID interactions (Kim et al. 2007).  However, there also was 
evidence for the presence of an exon 6-containing form.  Primers internal to exons 5 and 
6 amplified an RT-PCR product that was subsequently cloned and sequenced (Fig. 8).  
Additionally, the full length RT-PCR reaction mix was run on a gel and southern blotted 
with an exon 6-specific DNA probe. This “virtual” Northern revealed a band that 
migrated at the expected size--90nt larger than the cloned form (Fig. 9b).  The intensity 
of this band suggested that it was present in the RT-PCR product mix at two or three logs 
below the Brightlike∆ 6 form6 form that was cloned (Fig. 9b).  Because the data were derived 
from a nested PCR, we do not assume that they are quantitative. It is equally possible that 
amplification of the ORF of the exon 6-less form is favored by PCR because of its shorter 
length or other amplification artifacts.   We have no further data concerning the relative 
expression levels of an exon 6-containing versus an exon 6-lacking form of Brightlike in 
mouse.   
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3.2.3  DETECTION OF BRIGHTLIKE/ARID3C IN ORGANS OF IMMUNOLOGICAL 
SIGNIFICANCE 
Brightlike/ARID3C was identified, amplified and cloned from murine testes, 
thymus and spleen (Fig. 10).  A full length form which includes the complete REKLES 
domain was amplified and cloned from the mouse spleen.  We also observed the C/A 
transversion at position 786 (previously identified in Brightlike∆6) in the full length 
transcript with the addition of another silent (C/T) change at residue 693.  An exon 6-
containing form also resides in the thymus (Fig. 8).  Other tissues tested (including liver, 
brain, and lung) did not express detectable levels of Brightlike mRNA (Fig. 10).      
 
3.2.4 THE TWO ISOFORMS OF BRIGHTLIKE/ARID3C ARE EXPRESSED 
DIFFERENTIALLY IN B AND T CELL POPULATIONS 
Magnetic cell sorting and/or flow cytometry was used to fractionate lymphoid 
cells to determine what subpopulations express detectable levels of Brightlike.   A region 
spanning exons 2 through 4 of Brightlike was PCR amplified in double positive 
thymocytes without using a nested PCR approach. This approach did not detect 
Brightlike in double negative thymocytes (data not shown).   However using primers to 
amplify a region from exons 4 through 7, Brightlike was barely detectable in both 
samples (Fig. 11).  Using this cDNA as a template, a region spanning the exon 4/5 
junction through exon 7 was amplified in both populations (Fig. 11).  An amplicon 
containing exon 6 was detected in double positive cells only, whereas an amplicon 
detecting an exon 6-less form was amplified in double positive cDNA only (Fig. 11).   
The cumulative amounts of the different isoforms of Brightlike in the double positive 
sample can explain how it was detected using a unnested PCR reaction of exons 2 
through 4.  Using the same nested PCR reaction to amplify regions 2 through 4, 
 43 
Brightlike was also detected in single positive CD4 and CD8 splenocytes (data not 
shown).  The exon 5 through 7 specific primers amplified an exon 6-containing region in 
both single positive samples, but an exon 6-less form was found only in CD4+ 
splenocytes (Fig. 11).   
Taken together, the data suggest that an exon 6-containing form of Brightlike is 
expressed throughout T cell development.  In constrast, the exon 6-less form is expressed 
in double positive cells and remains transcribed in peripheral CD4+ mature T cells but 
not in CD8+ T cells.   
A single cell suspension was made from spleen and labeled with CD43 magnetic 
MicroBeads (Miltenyi Biotec Inc. Auburn, CA) according to manufacture’s protocol. 
CD43 antigen is expressed on the majority of leukocytes except for the immature and 
mature resting B-2 cells.  Cells were separated using a LS column.  Unlabeled cells were 
collected to enrich the B cell population.  The eluted CD43+ cells and 1/3 of the 
unlabeled cells were directly lysed in Trizol (GibcoBRL) and frozen at -80°C.  The 
remaining CD43- cells were cultured for 3 days either with LPS or with LPS+IL4+anti-
CD40 to induce B cell differentiation.  After 3 days RNA was extracted from cultured 
cells along with the CD43- and CD43+ unstimulated cells.  Amplicons of the correct size 
for Brighlike were detected in all samples (Fig. 12).  Full length Brightlike was only 
detected in the cells cultured with LPS, whereas Brightlike∆ 6 was in 6 was in all samples.   
These results indicate that full length Brightlike expression is induced in 
mitogenically stimulated B cells.  An increase in a Bright/DNA complex has been 
reported in LPS stimulated B cells (Webb et al. 1991).  LPS, which makes murine B cells 
proliferate, express (Nezlin and Lefkovits 1998) and secrete IgM and switch to produce 
IgG2b and IgG3 independent of T cells (Ström et al. 2002).  Cells which have also 
stimulated with IL4 and anti-CD40 which are used to mimic Th2 helper T cells to 
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activate IgE antibody production (N Nakanishi et al. 1996, Jeppson et al. 1998) but also 
switch to IgG1, IgG3, and IgG4 (Ström et al. 2002).   
 
3.2.5 GFP-FULL LENGTH BRIGHTLIKE FUSION PROTEIN IS DISTRIBUTED AMONG 
THE CYTOPLASM AND NUCLEUS WHEREAS GFP-BRIGHTLIKE∆6 IS PRIMARILY 
NUCLEAR.   
Bright has been shown to shuttle between the nucleus and cytoplasm in a CRM1-
dependent manner.  This shuttling is necessary for its transcriptional activity (Kim and 
Tucker 2006).  LMB is an inhibitor of CRM1 and blocks CRM1 dependent nuclear 
export of Bright. Conversely, CRM1 overexpression significantly increases cytoplasmic 
localization of Bright (Kim and Tucker 2006).  Bright does not contain a classical NLS, 
although several residues within the REKLES-α  domain are required for nuclear 
localization, a region conserved in Brightlike. The NES of Bright has been mapped to the 
REKLES-β -the domain excluded in Brightlike∆ 6.  6.  Four residues within REKLES-β  that 
have been shown to be required for nuclear export are all conserved among the ARID3 
family.   
Based on Bright’s REKLES-β  dependent nuclear export, we expected full length 
Brightlike to be localized in the nucleus and cytoplasm and the Brightlike∆ 6 form to 6 form to 
reside preferentially in the nucleus.  An N-terminally fused full length GFP-Brightlike 
was constructed and transfected into NIH 3T3 fibroblasts.  As observed for Bright (Kim 
and Tucker 2006), full-length Brightlike localized within both the cytoplasm and nucleus 
(Fig. 13a).  Based on the requirement for exon 6 (REKLES β )-encoded NES activity of 
Bright (Zong et al. 2000), we anticipated that the exon 6-deficient form of Brightlike 
would be retained in the nucleus (NLS is predicted to reside in exon5/REKLES-α  NES is 
predicted to reside in the exon6/REKLES-β ; Fig. 2).  This was the case in transfected NIH 
3T3 (Fig. 13a), 293T (Fig. 13b), or Cos7 cells (Fig. 14b).   
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3.2.6  MUTATION OF THE PUTATIVE SUMOYLATION SITE DOES NOT HAVE AN EFFECT 
ON SUBCELLULAR LOCALIZATION OF GFP-BRIGHTLIKE IN NIH 3T3 CELLS 
Sumoylation has often been linked to substrate cellular localization (reviewed in 
Zhong et al. 2000 and Gill 2005).  It has been associated with the nuclear pore complex 
and compartments within the nucleus, the nuclear periphery and nuclear bodies (reviewed 
in Hay 2005 and Dohmen 2004) and has been implicating in regulating nuclear pore 
transport (Hay 2005, Dohmen 2004 and Zhang et al. 2002).  Recently Bright has been 
localized in lipid rafts where it does not appear to be sumoylated and is thought to be 
involved in B-cell receptor signaling (C. Schmidt, pers. commun.).  This work has 
recently progressed and the data suggests sumoylation discharges Bright from lipid rafts.  
Bright with mutations in either the NES or NLS is not found in rafts. Thus, it was 
proposed that nucleocytoplasmic shuttling is required for accumulation of Bright in rafts.  
To examine the effect of sumoylation on localization of Brightlike localization, GFP-
Brightlike or its sumoylation mutant were transiently transfected into various cell lines, 
and localization was be determined by GFP expression.  Mutation of the putative 
sumoylation site had no apparent effect (Fig. 14). 
 
3.2.7 BRIGHTLIKE/ARID3C PROTEIN IS DETECTED IN CELL LINES BUT NOT MURINE 
TISSUE LYSATES 
Endogenous protein localization not only gives insight to function but is also 
useful in planning experimental assays that are more efficient in systems that do or do not 
contain endogenous Brightlike.  Furthermore, in the experiments described in Section 
3.3, we test the hypothesis that Brightlike works together with Bright.  Therefore, we felt 
it was informative to determine parallel spatial and temporal gene expression of Bright 
and Brightlike.  Based on its absence from EST databases and on our difficulty in 
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detecting it, Brightlike was shown to have low and restricted levels of expression within 
B and T cells.  While low levels of transcript generally correlate with low protein levels, 
it is possible that Brightlike protein accumulates because of a long half-life.   
In order to determine protein expression patterns, Western blots and 
immunostaining were performed on various tissues and cell lines employing an anti-
Brightlike polyclonal rabbit antisera specific to either N-terminal or C-terminal regions 
bearing no significant similarity to Bright or Bdp.  Full-length Brightlike has a predicted 
molecular weight of 45 kD and the splice variant has a size of 40 kD. As a positive 
control, NIH 3T3 cells transfected with the GFP-Brightlike were employed.  Specific, 
over-lapping expression patterns were observed in immunostains using either anti-
Brightlike or anti-GFP (Fig. 13b). Brightlike was undetectable in tissues whole cell 
lysates (data not shown) but was identified in Jurkat (human T-cell) and Raji (murine B-
cell) cell line nuclear extracts (Fig. 15).  mRNA expression was confirmed in both cell 
lines (data not shown).  There was no loading control performed so I cannot conclude that 
the other cell lines tested do not contain Brightlike protein.  Brightlike transcript in these 
other cell lines by RT-PCR was also not tested.  Immunostaining of cell lines was 
inconclusive.  Anti-Brightlike stained cells were indistinguishable from my pre-immune 
serum negative control.  Brightlike protein can be detected by Western blot analysis from 
at least two cell lines, whether anti-Brightlike antisera can detect protein from normal 
cells/tissues by Western analysis or endogenous protein levels by immunofluorescence 
will need further examination.   
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3.2.8 BRIGHTLIKE/ARID3C IS LOCALIZED TO LIPID RAFTS AFTER B CELL 
STIUMLATION 
We have shown that a small fraction of Bright localizes with the antigen receptor 
in plasma membrane-associated lipid rafts of resting B cells (C. Schmidt et al, submitted).  
Bright’s association with lipid rafts appears to be dependent on post-translational 
modification.  A palmitoylated pool of Bright is diverted to lipid rafts of resting B cells 
where it associates with signalosome components. Following BCR stimulation with anti-
µ and anti-CD19, Bright associates with sumoylation enzymes, inhibits phoshorylation of 
Btk and TFII-I, and then leaves lipid rafts as a sumoylated form.  Bright sumoylation 
mutants are trapped in lipid rafts after stimulation (Schmidt et al. submitted).   
To determine if Brightlike shares this novel feature, we fractionated lipid rafts 
from resting and stimulated B cell lines, prepared protein lysates from them, and 
performed western analyses (Fig. 16).  Brightlike was specifically detected in lipid rafts 
of Raji and Ramos, but surprisingly, in the reciprocal fashion as that of Bright.  That is, 
Brightlike accumulates in lipid rafts after stimulation with anti-CD19 and anti-µ. This 
suggests that, at least in this context, Brightlike and Bright expression, and presumably 
function, segregate.  
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Figure 3.  Protein Alignment of human, mouse and rat Brigthlike with other ARID 
paralogs.  Sequences were aligned using clustal-W.  This alignment helped predict the 
open reading frame of Brightlike by using Bright and Bdp known sequences and 
intro/exon junctions which are indicated by the red lines. 
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Figure 4.  Human and mouse ARID3C/Brightlike protein are highly conserved.  
NCBI Blast was used to align human and mouse ARID3C/Brightlike protein.  mouse and 
human Brightlike.  Overall the sequences were ~85% conserved and 100% identical in 
the ARID domain. 
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Figure 5.    ARID3 alignment was used to predict the translational start site for 
Brightlike.  The start site for other ARID3 members were previously investigated and 
used to predict the start site for Brightlike.  Bright contains an ATG start codon upstream 
of the putative start sites for Bdp and Brightlike but this possible start codon is not found 
in other ARID3 members.  Each residue is represented by a different color to visualize 
conservation.  The Kozak consensus sequence is present at all ARID start sites.  The 
Kozak sequence, which occurs on eukaryotic mRNA, plays a major role in the initiation 
of translation process.  Its consensus sequence is (gcc)gccRccAUGG, where R is a purine 
(adenine or guanine) three bases upstream of the start codon (AUG), which is followed 
by another guanine.  
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Figure 6.  ARID3C/Brightlike SUMOplot™ provided by Loren Probst.  The score 
system is based on direct amino acid match to the SUMO consensus sequence observed 
and shown to bind Ubc9 or substitution of the consensus amino acid residues with amino 
acid residues exhibiting similar hydrophobicity.  The first lysine of the KK1 motif is the 
putative sumoylation sight (K284) which is mutated in following experiments.  The 
consensus sequence appears to be conserved across species shown.  Species 
abbreviations: Hs, Homo sapiens; Pt, Pan troglodytes (chimpanzee); Cf, Canis familiaris 
(dog); Mm, Mus musculus (mouse); Rn, Rattus norvegicus (Norway rat); Bt, Bos Taurus 
(bovine). 
 
 
 
 52 
 
 
 
Figure 7.  eARID nested primers amplify Brightlike and other eARIDs in murine 
spleen.  Degenerate and non-degenerate eARID RT-PCR nested primers were designed 
to amplify the ARID region of Bright, Bdp, and the putative Brightlike from murine 
spleen DNA.  Lane 1 was amplified with degenerate outer primers and a degenerate 
nested forward primer with a Bright specific reverse primer.  Lane 2 has all degenerate 
primers with a Bdp specific reverse primer.  Lane 3 was amplified with Brightlike 
specific outer and inner primers.  Lane 4 has Brightlike specific primers with a 
degenerate nested forward primer.  Lanes 5, 6, 7, and 8 used a Bright plasmid control for 
the specificity of the primers.  5 and 6 should amplify Bright only because of a Bright 
specific nested reverse primer, 7 Bdp nested reverse, and 8 Brightlike nested reverse 
primer.  Primers used can be found in Appendix A.  The amplicon was cloned, sequenced 
and verified as Brightlike. 
 
 
 
 53 
 
 
 
 
 
 
 
 
 
Figure 8.  Exon 6 encoding the REKLES β  domain can be amplified from murine 
thymus after 3 rounds of PCR.  (A) Full length amplification of Brightlike. Outer 
primers were designed in the 5’ and 3’ UTR, inner primers amplified the start to stop 
codons   (B) Detection on exon 6 in PCR reaction.  The nested PCR rxn from the thymus 
was used as a template to amplify a region containing fragments of exons 5 and 6.  
Primers can be found in Appendix A. 
 
2nd nested from 
Spleen           Testes   Thymus 
A B 
Denotes Brightlike∆6 (1140 bp) 
Thymus 
     Exon 6 
containing 
fragmnet in 
thymus 
nested PCR 
reaction  
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Figure 9.   An exon 6 encoding full length Brightlike can be detected in murine 
spleen.  (A) Full length PCR products were run on a 1% agarose gel and subjected to (B) 
Southern blotting (virtual Northern) using an exon 6 or exon 4 specific probe.  An 
amplicon of the predicted size (1230 bp) was detected in murine spleen.  These PCR 
reactions were used as template for an exon 6 specific PCR reaction and no amplicon was 
detected (C).  Brightlike containing plasmids were used as a control to determine the 
amount of DNA necessary for probe detection (D).  200 pg of DNA could be detected 
overnight. 
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Figure 10.  Brightlike is expressed in tissues of immunological significance.  The 
open reading frame of Brightlike can be PCR amplified from the murine spleen, thymus 
and testis and human tonsil after a nested PCR approach.  In all 4 positive tissues this 
fragment was subcloned as alternatively spliced exon 6, which encodes the REKLES β  
domain and is named, Brightlike∆ 6.  Full length Brightlike 6.  Full length Brightlike was identified in murine 
spleen and thymus.  The human tonsil clone also contained a deletion in the ARID 
domain which was not predicted within exon 4. This splice does not correspond to a 
normal appearing GT-AG intron junction when compared to the genomic sequence.
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Figure 11.  The two isoforms of Brightlike are differentially expressed in T cell 
populations.  Double positive or double negative thymocytes were sorted by flow 
cytometry. Single positive splentocytes were separated using CD4 or CD8 magnetic 
MicroBeads (Miltenyi Biotec Inc.), and cDNA was created by RT-PCR.  Primers used  
spanned exon 6, so as to determine which isoform of Brightlike was expressed in these T 
cell populations.  An exon 6-encoding Brightlike was amplified in all populations, but an 
exon 6-less form was only detected in double positive thymocytes and CD4+ splenocytes.  
1 ug of full length Brightlike and Brightlike∆6 expression plasmids were used as positive 
controls.   
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Figure 12.  Full length Brightlike is expressed in CD43- splenocytes mitogenically 
stimulated with LPS.  Splenocytes were separated into CD43+ and CD43- populations 
using CD43 MicroBeads (Miltenyi Biotec Inc).  CD43- resting B2 cells were cultured for 
3 days with LPS or LPS, IL4 and anti-CD40.  Using RT-PCR analysis an exon 6-less 
encoding Brightlike was detected in all samples but an exon 6 containing brightlike was 
upregulated in CD43- cells cultured with LPS.
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Figure 13.  The two isoforms of Brightlike have different subcellular distribution.  
(A) Full length Brightlike localized to the cytoplasm and nucleus, whereas 
Brightlike∆6 is primarily nuclear.  NIH 3T3 cells were transfected with GFP-Brightlike. 
48 hr-post-transfection, cells were harvested, fixed and analyzed by fluorescence 
microscopy. Brightlike∆6 was primarily nuclear, consistent with REKLES β -dependent 
nuclear export.  (B) Brightlike antibody specifically immunostains GFP-Brightlike.  
GFP-Full length Brightlike was transiently expressed in 293T cells and subjected to 
indirect immunofluorescence to test the Brightlike polyclonal antisera made in New 
Zealand white rabbits with the N-terminal or C-terminal portion of Brightlike. 
 
 
 
Merge 
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Figure 14.  Mutation of the putative sumoylation site does not have an effect on 
Brightlike localization.  A.  NIH 3T3 cells were transfected with GFP-Brightlike, 
Brightlike∆6, BrightlikeK284R or Brightlike∆6K284R.  Both isoforms of Brightlike 
showed similar subcellular distribution as their putative sumoylation mutants.  Pictures 
taken with 100x objective.  B.  Cos-7 cells were transfected with GFP-Brightlike, 
Brightlike∆6, BrightlikeK284R or Brightlike∆6K284R.  Both isoforms of Brightlike 
showed similar subcellular distribution as their putative sumoylation mutants.  Nuclei 
were not stained becaused these cells were used for the in vivo sumoylation assay.  
Pictures taken with 40x objective. 
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Figure 15.  Detection of endogenous Brightlike protein expression in M12.4 murine 
B cell and Jurkat human T cell lines.  Nuclear extracts were run on an SDS-PAGE gel 
and subjected to Western blot analysis using anti-Brightlike polyclonal antibody. Under 
these conditions, the two Brightlike isoforms are indistinguishable in size.  Equal loading 
was not confirmed by blotting so this does not conclude that Brightlike is not in these 
other cell lines.   
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Figure 16.  Brightlike localizes to lipid rafts after B-cell receptor stimulation.  Raji 
and Ramos B cell lines were stimulated with anti-CD19 and anti-µ to mimic B-cell 
receptor engagement.  Lipid rafts were isolated and Western blotted for Brightlike, 
Foxp1, Bright or Raftlin to show raft isolation.  A band specifically stained with anti-
Brightlike antibody of the predicted size appeared in rafts after B-cell stimulation.  This 
assay was preformed in collaboration with Dr. Christian Schmidt. 
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3.3 Functional Analysis of Brightlike/ARID3C 
3.3.1 BRIGHTLIKE/ARID3C HAS A REKLES-DEPENDENT ASSOCIATION WITH 
BRIGHT/ARID3A   
Amino acids 521-541 of the REKLES domain are required for homo- and hetero-
interactions of Bright with itself or with Bdp (Kim et al. 2007).  This region is highly 
conserved within exon 6 of Brightlike.  We expected full length Brightlike to interact 
with Bright and Bdp (and to homo-dimerize) via its REKLES domain and its splice 
variant, Brightlike∆6, would not be able to undergo either self- or hetero-association.  
Brightlike association with Bright was tested by co-immunoprecipitation (CoIP) of 
proteins transfected into non-lymhoid cells which do not endogenously express them.  
293T cells were transfected with a combination of PCR3.1 HA-Brightlike or Brightlike∆6 
and empty GFP or GFP-Bright.  The conditions for Bright-Bdp interaction in non-
lymphoid cell lines are known (Kim et al. 2007) and were used in these experiments.  To 
confirm association of the endogenous counterparts, antibody raised against Brightlike 
was used for immuoprecipitaton and anti-HA or anti-GFP was used for Western blot 
analysis.  Anti-Brightlike precipitated both isoforms of Brightlike but did not co-
precipitate Brightlike∆ 6 and Bright6 and Bright (Fig. 17).  This result is consistent with the notion that 
REKLES-β  is needed for formation of Bright/Brightlike complexes.   
 
3.3.2 BRIGHTLIKE (BUT NOT BRIGHTLIKE∆6) BINDS TO MAR REGIONS UPSTREAM OF 
THE IGH S107 VARIABLE REGION 
Both transcription factors and cis-acting elements have been implicated in 
regulating gene accessibility.  MARs have been linked to chromosomal organization by 
allowing enhancers to act over large distances and associating with the nuclear matrix 
(Glazko et al. 2003).  Bright is a MAR binding protein and may regulate transcription by 
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altering chromatin structure.  Bright and Bdp have been shown to bind MARs that both 
flank the intronic (Eµ) IgH enhancer and MARs (termed TX125 and Bf150) positioned 
upstream of the IgH S107 variable region (Fig. 18) (Herrscher et al. 1995).  The presence 
of the highly conserved ARID domain in Brightlike suggests that Brightlike might 
recognize and bind to the same IgH-associated MARs bound by the other ARID3 family 
members (Bright and Bdp).   
EMSAs were performed to examine Brightlike’s MAR binding ability in vitro. 
Since REKLES-β  (within exon 6) is required for self-association, and thus for Bright to 
bind to the IgH promoter region (Kim et al. 2007), Brightlike∆ 6 6 was predicted to not bind 
to these probes.  Radio-labeled DNA fragments containing the TX125 and Bf150 binding 
sites with and without an excess of nonspecific cold competitor DNA were incubated 
with in vitro translated (IVT) Brightlike or with nuclear extracts prepared from 
Brightlike-transfected cells. Protein-DNA complexes were resolved by non-denaturing 
gel electrophoresis.  Antibody supershift analysis was useful in confirming that Brightlike 
is responsible for the retarded migration of DNA probe.  Consistent with our hypothesis, 
Brightlike but not Brightlike∆ 66, bound to previously known Bright binding MARs (Fig. 
19).  Western blot analysis confirmed that Brightlike∆ 66 IVT protein levels were 
equivalent (data not shown). 
 
3.3.3 A POINT MUTATION WITHIN A CONSERVED RESIDUE IN THE ARID DOMAIN 
DISRUPTS IN VITRO BINDING OF BRIGHTLIKE TO THE S107 VH1-ASSOCIATED MAR 
A conserved tyrosine substitution in Bright’s ARID domain disrupts its ability to 
bind DNA (Nixon et al. 2004).  A Brightlike Y197A substitution mutant was generated 
by a PCR based mutation reaction.  Binding was assayed via EMSA as described above.  
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In vitro translated wild-type Brightlike bound to Bf150 but its Y197A mutant did not 
(Fig. 19). 
 
3.3.4 MUTATION OF THE PUTATIVE SUMOYLATION SITE DID NOT HAVE AN EFFECT 
ON BRIGHTLIKE’S IN VITRO ABILITY TO BIND BF150. 
To examine whether SUMO modification of Brightlike alters DNA-binding 
ability, wildtype and K284R-Brightlike were generated in vitro and employed in EMSAs 
with a radiolabeled Brightlike-binding site. It is rare for in vitro translated proteins to 
undergo post-translation modification by SUMO. Thus, as expected, in vitro translated 
Brightlike K284R bound to BF150 (Fig. 19).  Whether sumolation has an effect of 
Brightlike’s binding in vivo will need further investigation.   
 
3.3.5 BRIGHTLIKE  AND BRIGHT BIND INDPENDENTLY TO THE SAME 107 VH1-
ASSOCIATED MAR  
Since Brightlike binds to the same endogenous sequences as Bright, it would be 
useful to determine if Brightlike interferes, competes or synergizes with Bright binding.  
Titration of Brightlike at varying concentrations into Bright-DNA reactions might either 
increase or decrease Bright binding.  If Brightlike is a component of the endogenous 
Bright mobility shifted complex, then the Brightlike antibody would produce supershifted 
Bright EMSA bands, whereas pre-immune serum or irrelevant antibody would not.  As 
shown in Fig. 20, we observed no Bright/Brightlike:DNA complex on Bf150 (Fig. 20).  
Also Brightlike did not inhibit Bright’s binding under protein concentration and probe 
conditions in which we have observed competition of Bright binding by Cux/CDP (Wang 
et al. 1999) or by Bdp (D Kim, unpublished results).   
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3.3.6 BRIGHTLIKE-BRIGHT-DNA COMPLEXES ARE RECRUITED TO CHROMATIN  
To examine whether Brightlike binds to IgH-associated MARs in vivo, chromatin 
immunoprecipitation (ChIP) experiments were performed using AB1.2 hybridoma cells 
which express the rearranged S107 V gene as an IgA antibody.  Proteins bound to DNA-
(or proteins bound to these proteins) were cross-linked with formaldehyde in vivo.  
Chromatin was isolated and sheared into small fragments.  Bright or Brightlike antibody 
was used to precipitate the complex. Pre-immune serum or anti-monoclonal IgG were 
used as controls.  Western blot analysis using anti-Bright showed that anti-Bright and 
anti-Brightlike precipitated Bright containing chromatin and pre-immune serum and IgG 
did not (Fig 21a).  Thus, Bright-Brightlike complexes are recruited into the chromatin 
fraction of these cells. 
The ChIP was repeated using another S107-expressing B cell line, BCg3R-1 
(Cerny et al. 1988).  As shown in Fig. 21b, Brightlike antisera preferentially precipitated 
a Bright/DNA complex from these cells as well.  
Whether Brightlike and/or Brightlike-Bright complexes are specifically recruited 
to MAR regions of Eµ or S107 VH1 in vivo is unclear.  Following reverse cross-linking 
the immunoprecipitated DNA of AB1.2 cells was amplified by PCR using primers 
specific for these regions or for β -actin as a control.  Primers specific for the S107 VH1 
region were not informative, as all samples including the negative controls, amplified a 
band of the correct size (data not shown).  Efforts are underway to resolve these 
problems. 
 
3.3.7 BRIGHTLIKE INCREASES TRANSCRIPTION FROM THE HEAVY CHAIN PROMOTER    
Given that Brightlike binds to the S107 VH1 promoter region in vitro and interacts 
with Bright, we predicted that Brightlike would have an effect on immunoglobulin gene 
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transcription.  Based on our data using a REKLES-β  Bright mutant (Kim et al. 2007), 
Brightlike∆6 was not expected to act as a dominant negative in transactivation.  NIH3T3 
BTP cells (Bf150, TX 125 promoter) were stably transfected with a VH1 S107 heavy 
chain promoter region fused upstream of firefly luciferase and utilized to determine if 
Brightlike also enhances or represses transcription of this locus.   
Bright, along with wild type Brightlike, BrightlikeK284R, or Brightlike∆6 were 
transiently transfected into S107 transcriptional reporter line (NIH3T3 BTP; described 
above), and luciferase activities were measured relative to co-transfected renilla 
luciferase control.  As shown in Fig. 22, Brightlike had a modest, positive effect on 
luciferase expression (lane 3). In the presence of Bright and Brightlike luciferase activity 
was increased ~2-fold (relative to empty vector; lane 4).  A mutant in which the predicted 
sumoylation conjugation motif of Brightlike was altered (BrighlikeK284R) had a stronger 
(~3.4 fold) enhancement on reporter activity (lane 5).  This is consistent with the 
prevailing model (reviewed in Gill 2005) in which sumoylation inhibits transcription 
factors, if we assume that the wildtype K284 form of Bright is sumoylated in 3T3 
fibroblasts.  Using a Bright sumoylation mutant may increase this effect.  This 
experiment was repeated and error bars are shown. 
.   
3.3.8 BRIGHTLIKE INCREASES THE RATE OF MOUSE EMBRYONIC FIBROBLAST (MEF) 
GROWTH 
Human Bright has been shown to immortalize primary MEFs and to rescue them 
from natural senescence or Ras-induced senescence (Peeper et al. 2002).  As a first 
approach for addressing this issue for Brightlike, E13.5 BALB/c MEFs were transiently 
transfected with GFP-Brightlike, GFP-Brightlike∆6, or empty GFP.  Prior to transfection 
the MEFs had progressed through 8 cell divisions, and thus, grew slower than freshly 
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isolated counterparts (data not shown).  There was a significant increase in MEF growth, 
as determined by total cell numbers in Brightlike transfected cells as compared to the 
empty vector control (Fig. 23).  These results indicate that, as with its other ARID 
paralogs, Brightlike/ARID3C has growth enhancing activity.  Thus, we have embarked 
on the senescence rescue studies described below. 
 
3.3.9  OVEREXPRESSION OF BRIGHTLIKE OR BRIGHT RESCUES BTR CELLS FROM 
RAS INDUCED SCENESCENCE 
Premature senescence of 'tsT' MEFs (of BALB/c genetic background) that express 
a temperature-sensitive mutant of SV40 large T antigen (LT) were used to generate a cell 
population stably expressing RasV12 (BTR cells) (Peeper et al. 2002). These cells 
proliferate rapidly at the permissive temperature (32 °C) but undergo premature 
senescence at the restrictive temperature (39.5 °C).  Vectors encoding GFP-only or 
fusions of GFP with Bright, Brightlike, Brightlike∆6, or their putative sumoylation 
mutants were transiently transfected into BTR cells.  GFP imaging indicated that all that 
all constructs were expressed at ~70% efficiency 48 hours post-transfection (data not 
shown).  Cells were split 2 days post transfection and fixed 7 days post transfection.  As 
expected, GFP-only expressing BTR cells stained positively for acidic β -galactosidase 
activity at the nonpermissive temperature (39.5°C) at which the T antigen is degraded 
(Fig. 24).  In contrast, cells transfected with Bright or the Bightlike constructs bypassed 
RASV12-mediated senescence (viable and staining pink in Fig. 24).  Mutation of the 
putative sumoylation site had no effect on Brightlike’s ability to rescue BTR cells from 
premature senescence. 
Together with the results in the previous section, we conclude that Brightlike as 
well as its alternatively spliced or Sumo-I-site mutated forms, can rescue both 
 68 
spontaneous and RASV12-induced replicative senescence when ectopically introduced 
into fibroblasts.   
 
3.3.10  ARID PROTEINS SEQUESTER RAS TO LIPID RAFTS 
The GTPase signaling molecule, Ras, is localized to lipid rafts (reviewed in 
Parton and Hancock 2004).  Futhermore it has been observed that the movement of Ras 
in and out of lipid rafts is necessary for its signaling function (Shimizu 2001) for the 
reason that release of GTP-Ras is needed for Raf activation (Prior et al. 2001).  Thus 
movement of Ras out of rafts is necessary for activation of proliferation and consequently 
senescence.  Given our observations (Fig. 16) that Brightlike and Bright transient in and 
out of rafts in response to antigen receptor signaling, we felt an initial approach to the 
mechanism of senescence rescue might be focused here. BTR cells were transiently 
transfected with vectors encoding nothing, GFP-only GFP-Bright, GFP-Brightlike, GFP-
Brightlike∆6, or their putative sumoylation mutants. Transfected cells were cultured at 
32°C or 39.5°C, and then 48 hours post tansfection, lipid raft or plasma membrane 
fractions were isolated.  At the permissive temperature (32°C), ARID members were 
found in the plasma membrane fraction and Ras was found in rafts (Fig. 25).  At 39.5°C 
ARID proteins were found in rafts along with Ras.  Without ARID overexpression, Ras 
was found in the membrane fraction at the non-permissive temperature (39.5°C; lane 7).  
Therefore ARID proteins-by going into rafts—may block the ability of Ras to leave and 
thus interfering with senescence signaling, thereby by-passing Ras-induced senescence.  
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Figure 17.  Brightlike, but not Brightlike∆6, associates with Bright.  293T cells were 
transiently co-transfected with GFP-Bright and HA-Full length Brightlike (HA-FLBL) or 
HA-Brightlike∆6 (BL∆6). Whole cell lysates were prepared 48 hr later and then subjected 
to co-immunoprecipitation (CoIP) with Brightlike antisera or pre-immune serum (P.I.) as 
a negative control.  As predicted, full length Brightlike precipitates Bright and 
Brightlike∆6 does not. 
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Figure 18.  Schematic of the rearranged S107 VH1-IgH locus (adapted from Herrscher 
et al. 1995).  Bright and Bdp have both been shown to bind the MARs positioned 
upstream of the IgH S107 region, termed TX125 and Bf150.  The S107 VH1  gene 
segment rearranged with Dsp20 and JH1 encodes the heavy chain of the T15 idotypic 
antibody which is preferentially selected in the response to phosphorylcholine (PC) 
expressed on the capsule of bacterium such as Streptococcus pneumoniae (Malipiero et 
al. 1987). 
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Figure 19.  Full length Brightlike, but not Brightlike Y197A or Brightlike∆6, binds to 
S107 VH1 promoter-associated MAR in vitro. In vitro translated Bright, full length 
Brightlike or Brightlike∆6 were incubated with Bf150 and subjected to an electrophoretic 
mobility shift analysis.  Bright and full length Brightlike formed protein/DNA complexes 
that could be supershifted with anti-Bright or anti-Brightlike (or anti-HA) antibody and 
Brightlike∆6 did not. Mutation of a conserved tyrosine in the ARID domain of Bright and 
of Brighlike disrupts their ability to bind DNA. 
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Figure 20.  Brightlike binds to the same IgH specific DNA probes as Bright, but does 
not bind together nor inhibit Bright’s binding.  In vitro translated Myc-Bright and 
HA-Full length Brightlike were incubated with Bf150 and subjected to an electrophoretic 
mobility shift assay (EMSA).  Bright and full length Brightlike formed protein/DNA 
complexes that could be supershifted with anti-Bright (or anti-Myc) or anti-Brightlike (or 
anti-HA) antibodies, but they did not form Bright/Brightlike/DNA heterocomplexes 
under the conditions employed. 
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Figure 21.  A.  Anti-Brightlike antibody immunoprecipitates Bright associated 
chromatin from AB1.2 cells.  To examine whether Brightlike binds to IgH-associated 
MARs in vivo, chromatin immunoprecipitation (ChIP) was performed using AB1.2 
hybridoma cells because they express the S107 V gene.  Proteins bound to DNA-(or 
proteins bound to these proteins) were cross-linked with formaldehyde in vivo.  
Chromatin was isolated and sheared into small fragments.  Bright or Brightlike antibody 
was used to precipitate the complex, pre-immune serum or IgG were used as negative 
controls.  Western blot analysis using anti-Bright clearly showed that anti-Bright and 
anti-Brightlike precipitated Bright containing chromatin and pre-immune serum and IgG 
did not.  B.  Anti-Brightlike antibody immunoprecipitates Bright associated 
chromatin from Bcg3R-1d cells.    The ChIP was preformed as described above but pre-
immune serum from the rabbit used to make anti-Brightlike antibody was used as a 
control.   
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Figure 22.  Brightlike effects luciferase activity downstream of the S107 promoter.  
NIH3T3 cells stably transfected with a luciferase reporter construct were transiently 
transfected with Bright, Brightlike, or a combination of Bright and Brightlike, Brightlike∆ 
or BrightlikeK284R and a renilla construct.  Luciferase activity was measured and 
normalized with renilla expression.  Values are plotted relative to 100% for the empty 
vector control. The largest increase in luciferase expression (~3.3 fold) was seen when 
Bright and BrightlikeK284R (mutation of the putative sumoylation site; lane 5) consistent 
with the idea of sumoylation inhibiting transcription.  This experiment was repeated and 
error bars are shown. 
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Figure 23.  Brightlike expression extends the growth of mouse embryonic fibroblasts 
(MEFs).  MEFs were transfected with GFP tagged full length Brightlike or Brightlike∆6.  
48 hours post-transfection, cells were split into four 6-well plates (day 0).  On days 5, 7, 
10 and 12 MEFs were counted from individual plates.  Transfection efficiency was 
monitored by GFP expression. 
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Figure 24.  Brightlike and Bright rescue BTR cells from premature 
senescence. BTR cells, mouse embryonic fibroblasts transformed by temp. sensitive 
SV40 tag and RASV12 , were transiently transfected with GFP alone or with GFP 
fusions of Bright, Brightlike, Brightlike∆6, or their putative sumoylation mutants.  GFP 
expression indicated that cells were uniformed transfected at ~70% when imaged 48 
hours post-transfection (data not shown).  Cells were split 2 days post transfection and 
fixed 7 days post transfection.  As expected empty GFP expressing BTR cells stained 
positive for acidic β -galactosidase activity (blue staining with X-gal) at 39.5°C 
(conditions in which T antigen is degraded).  Cells transfected with Bright or the 
Brightlike constructs remained viable and in cycle (counter-stained pink by Eosin), 
indicative of bypassing senescence.  Untransfected cells or cells transfected with empty 
GFP were blue (indicative of senescence).  These results were duplicated in 2 
independent experiments.
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Figure 25.  ARID proteins sequester Ras to lipid rafts.  BTR cells were transiently 
transfected with the indicated GFP-fusion constructs and cultured at 32°C or 39.5°C.  48 
hours post-transfection, lipid raft or plasma membrane fractions were isolated.  At the 
permissive temperature (32°C) ARID members were found in the plasma membrane 
fraction and Ras was found in rafts.  At 39.5°C ARID proteins were found in rafts along 
with Ras.  Without ARID overexpression, Ras was found in the membrane fraction at the 
non-permissive temperature (39.5°C; lane 7). 
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CHAPTER 4: CONCLUSIONS AND DISCUSSION 
4.1 BRIGHTLIKE IS A BONA FIDE TRANSCRIPT WITH AT LEAST 2 ISOFORMS AND IS 
EXPRESSED IN TISSUES OF IMMUNOLIGAL SIGNIFICANCE.   
Brightlike has been PCR amplified but this generally requires a nested approach 
suggestive of low transcript levels (Fig. 7, 10, 11, 12).  Its absence from EST databases 
suggested it was a rare transcript, perhaps only expressed at low levels, in a small subset 
of cells or after an environmental cue.  However its conservation in all vertebrate 
genomes examined suggests it is a critical gene.  Using a nested PCR approach we have 
show Brightlike is expressed in the murine spleen, thymus and testis, and human tonsil 
(Fig. 10); ie, tissues of immunological significance.   In order to test whether Brightlike 
functions in combination with Bright, it was necessary to assess their parallel spatial and 
temporal gene expression.   
The majority of cloned amplicons were an alternatively spliced form of Brightlike 
(Brightlike∆6) that does not include the highly conserved RELKES-β  domain shown to be 
necessary for Bright homo/heterotetramerization as well as its interaction with DNA.  It 
cannot be excluded that Brightlike∆ 66 may be favored over the full length form in PCR 
amplification.  Therefore it remains to be determined which is the more abundant isoform 
in relevant tissues/cells.  The two isoforms of Brightlike differentially localize (Fig. 13).  
Brightlike∆ 6 6 is primarily nuclear, while the full length form is distributed among the 
nucleus and cytoplasm.   
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4.2 THE TWO ISOFORMS OF BRIGHTLIKE HAVE DIFFERENTIAL EXPRESSION 
PATTERNS IN LYMPHOCYTE POPULATIONS 
The normal development of lymphoid cells including the control of proliferation 
is regulated by a complex interaction of proteins, some that mediate changes in chromatin 
structure. We have shown that the full length form of Brightlike is expressed in all 
subpopulations of T cells tested (DN, DP, CD4SP and CD8SP; Fig. 11). However, 
Brightlike∆6 is only expressed in DP and CD4+ T cells.  This suggests that the isoforms 
may play differential roles in T-cell development.  Brightlike∆6 is not predicted to act as a 
dominant negative, since it does not bind to the same DNA regions as the full length form 
or interact with other ARID3 members.  Thus, we speculate that it may have a function of 
its own.  
There also seems to be differential expression of the two isoforms in B cells.  We 
measured isoform expression in resting CD43- conventional (B2) cells and in CD43- 
cells stimulated with LPS or with LPS+IL4+anti-CD40 (Fig. 12).  In resting B cells, 
Brightlike∆6 seemed to be the more abundant isoform.  However when these cells were 
stimulated with LPS, upregulation of the full length form was observed.  The faint 
Brightlike∆6 band in the nested reactions might have resulted from a small population of 
non-B cell contamination (CD43 negative selection retains ~3-5% non-B cells).  It was 
previously shown that Bright activity is upregulated in B cells mitogenically stimulated 
by LPS (Webb et al. 1991), consistent with the notion that Bright and full-length 
Brightlike may interact and work together in stimulated B cells.  The observation that the 
different isoforms are expressed differentially suggests this serves some specialized 
purpose in these cell fractions.  Determining the pathways the two isoforms regulate in 
murine lymphocytes should provide insightful information of immunological interest.   
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4.3 BRIGHTLIKE CONTAINS A SUMOYLATION CONSENSUS SEQUENCE 
Brightlike scored very high using SUMOplot™ (Fig. 6) to examine if the 
conserved sumoylation site found in Bright was predicted to be sumoylated in Brightlike.  
However, technical problems have prevented us from confirming this.  We are currently 
attempting to optimize an experiment in which GFP-Brightlike (or its putative 
sumoylation mutant, K284R) and GFP-SUMO-1 are covalently linked following their 
ectopic expression in COS-1 cells.  SUMO-1 is conjugated as a 92 amino acid 
polypeptide to internal lysines of substrate proteins. Mutation in the putative sumoylation 
residue would be expected to abrogate the higher mobility band (~11kD) resulting from 
this conjugation.  To investigate Brightlike sumoylation under cell-free conditions, 35S-
labeled wildtype and K284R Brightlike produced by in vitro translation will be incubated 
in the presence of ATP and purified fusions of GST with SAE1, SAE2, Ubc9, and 
SUMO-1 and analyzed by SDS-PAGE and autoradiography.  These assays will be 
performed in collaboration with Dr. Van Willson at Texas A&M University. 
Along with transcription factors and cis-acting elements, SUMO has also been 
implicated in chromatin organization.  PIAS proteins are a family of SUMO-I E3 ligases, 
which are thought to be structural anchors aiding in transcriptional regulation (Sharrocks 
2006).  The founding member of the PIAS family, PIAS1, was named for Protein 
Inhibitor of Activated STAT (Liu et al. 1998).  In addition to the RING E3 ligase domain, 
PIAS proteins contain a SAP domain which has been shown to bind MARs to the nuclear 
matrix. This finding provides a conceoptual link between sumoylation and transcriptional 
regulation by means of chromatin remodeling and nuclear matrix attachment (Sharrocks 
2006).  In many cases, PIAS proteins appear to function by means of the relocalization of 
transcription factors to different subnuclear compartments (Sharrocks 2006).  Bright 
function has been associated with its subnuclear localization (Zong et al. 2000).  In 
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association with LYSp100B, Bright acts as a transcriptional activator and is located in 
nuclear bodies called LANDs (Zong et al. 2000).  In association with Sp100, Bright no 
longer binds well to MARs, and therefore, its transcriptional activity may be repressed 
potentially through its re-localization into PML nuclear bodies (Zong et al. 2000).  
Bright, Sp100 and PML are all modified by the SUMO-1 and the sumoylated forms of 
PML and Sp100 show specific nuclear localization to NBs.  It is possible that MAR 
binding transcription factors repress transcription of their corresponding loci by their 
sequestration into NBs.   The localization of the loci also appears to affect the 
transcriptional activity.  IgH is localized to the nuclear periphery in non-expressing cells, 
and is re-localized more centrally in actively expressing cells (Kosak et al. 2002).   
Since Brightlike had the same conserved sumoylation sight as Bright, we 
hypothesized SUMO modification of Brightlike would either increase or decrease its 
trans-activation or repression potential.  If so, one can address the mechanism that 
underlies the effect.  SUMO-dependent repression or activation of Brightlike should be 
relieved by co-expression of sumo-specific proteases.  We hypothesized that mutations of 
the SUMO consensus site will enhance Brightlike’s activation potential and association 
with endogenous MARs in vivo.  Our lucifease experiments performed to date (Fig. 22) 
were consistent with this hypothesis.  Brightlike may function in the nuclear scaffold that 
localizes its binding sites to subnuclear compartments of activation or repression.  We 
predicted that SUMO-deficient Brightlike would show a more diffuse nuclear pattern 
compared to sumoylated Brightlike, which would be predicted to localize to the nuclear 
periphery or to NBs.  I did not detect any changes in localization of full length Brightlike 
when mutating the putative sumoylation site (Fig. 14).  However, this may be explained 
by cell context or exogenous levels of Brightlike, and again prompts the need to find a 
suitable source for endogenous protein analyses.   
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4.4 FULL LENGTH BRIGHTLIKE INTERACTS WITH BRIGHT AND BINDS TO THE SAME 
MAR REGIONS ASSOCIATED WITH BRIGHT 
Co-transfected GFP-Bright and HA-Brightlike can be co-immunoprecipitated in 
vitro.  Determining whether this occurs in vivo has been limited by the low abundance of 
Brightlike and will need further experimentation.  LPS blasts are a potentially good 
source for this, since both full length Brightlike and Bright transcripts are elevated there.  
In vitro translated Brightlike binds upstream of the IgH promoter at MARs termed Bf150 
(Fig. 19, 20) and Tx125 (data not shown) previously shown to bind Bright.  A mutation 
in the conserved ARID domain (Y197) disrupts either ARID protein’s DNA binding 
function (Fig. 19). As predicted, in vitro translated Brightlike∆ 66, which lacks the critical 
REKLES domain functions, fails to bind the MARs (Fig. 19).  Because Bright and 
Brightlike can be co-immunoprecipitated and bind to the same region of DNA it is likely 
that they form Bright/Brightlike/DNA complexes.  However, when in vitro translated 
Bright and Brightlike were incubated and subjected to an electrophoretic mobility shift 
assay they did not appear to form a distinct complex (Fig. 20).  There are several 
explanations that can explain this.  For example, a specific chromatin context is required.  
Or, additional transacting factors absent in IVT lysates might be necessary.  Also, 
because of biniding affinity differences, they might not form hetercomplexes in the 
presence of excess probe.  Consistent with one of the first two possibilities above, Bright 
and Brightlike could form a complex on chromatin in vivo (Fig 21).  However, it remains 
to be resolved whether this in vivo interaction is recruited specifically to IgH enhancer 
and promoter regions.   
Bright has been shown to interact with Bruton’s tyrosine kinase (Btk), the 
defective gene product in x-linked immunodeficiency disease, as evidenced by formation 
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of Bright-Btk mobility shifted complexes (Webb et al. 2000).  It has been shown that the 
transcription factor TFII-I, which binds to pyrimidine-rich initiator (Inr) regions, is 
phosphorylated by Btk and interacts with Bright at the Inr motif upstream of  VH1.  Both 
Btk and TFII-I are needed for maximal Bright-dependent transcription of IgH (Rajaiya et 
al. 2006).   Btk and TFII-I may be required for maximal Brightlike/DNA interaction and 
consequently transcription of IgH. 
 
4.5 ARID PROTEINS AND TUMORIGENESIS 
 The majority of ARID proteins have been linked to cell proliferation and 
tumorigenesis. However the mechanism is not always the same (reviewed in Patsialou et 
al. 2005).  Some ARID members are activators of proliferation (ARID1B, ARID3A, 
ARID3B, ARID4B, JARID1B and JARID1C).  Others are thought to inhibit cell growth 
(ARID1A, JARID1A and JARID2).  Several of these were found to be Rb binding 
proteins.  The mammalian SWI/SNF chromatin remodeling complex represents an 
example of how different ARID members might have opposing roles in proliferation.  
When ARID1A, as a component of the SWI/SWF complex, negatively controls 
proliferation; ie, acts as a tumor suppressor (reviewed in Klochendler-Yeivin et al. 2002).  
Accordingly, a deficiency in ARID1A has been found in several human cancers (Wang et 
al. 2004).  In contrast, ARID1B is required for promoter association by complexes in 
proliferating cells that activate both c-Myc and E2F1 (Nagl et al. 2007).  ARID3A/Bright 
was found in an unbiased screen in search of genes which collaborated with oncogenic 
Ras to contribute to tumorigenesis (Peeper et al. 2002).  ARID3B/Bdp was later found to 
contribute to malignant transformation of neuroblastoma (Kobayashi et al. 2006).  It was 
only natural that we examined the transformation properties of ARID3C/Brightlike. 
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4.6 BRIGHTLIKE RESCUES EMBRYONIC FIBROBLASTS FROM NATURAL OR 
PREMATURE SENESCENCE 
Here we showed that Brightlike can accelerate the growth of normal MEFs (Fig. 
23) and rescue BTR fibroblasts from RASV12-induced senescence-properties (Fig. 24) 
suggestive of a proto-oncogene.  Currently I am retrovirally expressing Bright and 
Brightlike in combination with established oncongenes (RasV12 and E1a) in MEFs to 
test futher of the role of ARID3 members in tumorigenesis.  I will determine whether 
Bright and Brightlike co-expression or Bright or Brightlike co-expression with RasV12 
or E1a results in their immortalization or in vitro transformation (foci formation in soft 
agar).  If either immortalization or transformation is established in cultured MEFs, I will 
determine if they form tumors in nude mice—the accepted in vivo definition of 
oncogenic transformation. 
To study the molecular mechanism by which Brightlike allows escape from 
senescence will also require further experimentation.  We hypothesize that eARIDs 
interact with and sequester Rb from E2F1 promoters, thus de-repressing the E2F pathway 
which drives cells through the G1/S transition.  Brightlike upregulation of G1 Cyclins 
will be measured in Brightlike-transformed MEFs.  Further molecular pathways that 
Brightlike regulates may be elucidated from microarray experiments.  It will be important 
to determine whether the observations in ectopically transduced fibroblasts are relevant to 
lymphocytes.  Toward this end, a mouse lymphochip or PCR based arrays using known B 
and T cell regulators of proliferation may be utilized to identify immune-related 
pathways.  These genes can be validated by PCR analysis of subpopulations expressing 
Brightlike.  Direct activation of these genes can be further examined by EMSAs or ChIP 
assays.  Identification of genes Brightlike may regulate will help to understand how it 
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contributes to immune system development and function or how it might promote the 
formation of leukemia/lymphoma.  
  Another possible mechanism for Bright’s role in proliferation can be explained by 
its association with the B-cell receptor.  Life and death of normal and malignant B 
lymphocytes rests in the hands of its cell surface receptor for antigen.  The status of this 
antigen receptor (e.g., other molecules that interact with it or mutations within it) can 
often contribute to the aggressiveness and clinical course of leukemia and lymphoma.  
Therefore, understanding how this receptor functions is important in understanding 
mechanisms that underlie B cell cancer.  My colleague, Christian Schmidt, has 
discovered that Bright can be found not only in the nucleus of B cells, where it functions 
as a complex with BTK and TFII-I to activate IgH transcription, but in a cholesterol-rich 
lipid raft domains of the B cell plasma membrane.  Stimulation of growth and 
differentiation through the antigen receptor results in Bright’s exit from lipid rafts.  
Bright and Brightlike trafficking in and out of lipid rafts may control the antigen 
receptor’s threshold to antigen signaling, thereby contributing to the malignant growth 
potential of the cell.  A possible mechanism for this can be explained by Ras 
sequestration into lipid rafts by Bright or Brightlike.  Ras activation is required for BCR 
mediated proliferation (Coughlin et al. 2005).  Futhermore movement in and out of rafts 
is required for Ras activation and therefore its signaling function (Shimizu 2001).  
ARID3 sequestration of Ras to lipid rafts would consequently interfere with Ras induced 
senescence.   
 
4.7 A ROLE FOR ARIDS IN SPERMATOGENESIS 
In addition to the immunological significant tissues, I have shown that Brightlike 
is expressed in the testes (Fig. 10).  Consistent with this, two of the rare Brightlike ESTs 
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were derived from pig testis and from a teratozoospermia microarray.  The testes express 
a broad range of genes during gametogenesis, and the biological significance of this is 
unknown (Hecht 1995).  Several ARID members have been shown to be expressed in the 
testes, including ARID1A, Bright/ARID3A, ARID4B, ARID5A and JARID1B, 
JARID1C, JARID1D (Fig. 1).  Of these, 2 ARIDs were thought to be restricted to the 
testes (Patsialou et al. 2005).  ARID4B (RBP1L1) has been shown to be expressed in 
several human carcinomas and in normal testis but not other tissues (Cao et al. 2001).  
JARID1B (PLU-1) was first thought to be restricted to the adult testes (Barrett et al. 
2002).  More recently, it has been shown to be expressed in mammory glands of pregnant 
humans and mice (Barrett et al. 2007).  JARID1B is more broadly expressed in the 
developing embryo (Madsen et al. 2002) and quite highly in mitotic spermatogonea 
(Madsen et al. 2003).  JARID1B is upregulated in both prostate and breast cancer (Xiang 
et al. 2007 and Lu et al. 1999). As with many of the ARID members, JARID1B interacts 
with Rb; more specifically, it stabilizes hypophosphorylated Rb, and as such, functions as 
a tumor suppressor.  Whether this is a function of JARID1B in the testes is unknown.  
ARID5B (MRF2/Desrt) expression is not restricted to the testes but has obvious role in 
testicular development.  ARID5B-deficient mice are uni- or bilaterally cryptorchid.  Their 
undescended testes are smaller and show disrupted spermatogenesis.  Accordingly, 
knockout male mice have reduced fertility with wild-type females (Lahoud et al. 2001).  
JARID1D, also known as SMCY, was mapped to a region necessary for spermatogenesis 
on the mouse Y chromosome.   This region is well conserved on the Y in mouse, man and 
even marsupials.  It is believed that JARID1D has histone demethylase activity through 
recruitment of a meiosis-regulatory protein to heterochromatin in males (Akimoto et al. 
2008).   Furthermore, a screen for Y chromosome abnormalities in infertile men 
identified JARID1D deletions in 8 out of 41 patients. However, this was accompanied by 
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deletion of other genes (Teng et al. 2007).  ARID1 (also known as p270) has been 
reported to be necessary for sperm motility. A phoshorylated form localizes to lipid rafts, 
suggesting a possible role in signaling events that lead to motility (Kaneto et al. 2008).   
As previously stated, Brightlike/ARID3A appears in the database as a pig testis 
EST and on a Teratozoospermia microarray.  Teratozoospermia is described as 
spermatozoa with abnormal morphology, and the condition is frequently coupled with 
infertility.   This microarray, which was prepared from sperm cells of males with 
consistent and severe teratozoospermia (ie, less than 4 percent of sperm cells are 
morphologically normal) showed an upregulation of Brightlike.  This suggests that 
Brightlike may also have a role in spermatogenesis.  I performed immunohistological 
staining of a testes section using Brightlike antisera. Strong Brightlike staining was 
observed in the newly formed spermatids and mature spermatozoa (Fig. 26).  The 
staining was considerably stronger then expected, based on the consistently low 
abundance of Brightlike message in other tissues.  Further experimentation is required to 
determine if Brightlike has a bona fide role in the testes or if it is merely a product of 
promiscuous expression.   
 
4.8 IMMUNE SYSTEM REGULATION AND SPERMATOGENESIS 
There are interesting correlations of immune system regulation and 
spermatogenesis.  For example, there is an association of autoimmune disorders and sex 
determination. Only 1 out of 9 patients with Systemic Lupus Erythematosus (SLE) is 
male.  Bright expression is restricted to certain B cell subsets, but also its message has 
been detected in the testes.  Recently Bright has been shown to be elevate in the 
peripheral B cells of SLE patients (personal communication with Dr. Carol Webb). 
Transgenic mice that overexpress a Bright transgene powered by the CD19 (B cell-
 88 
specific promoter) produce anti-nuclear antibodies (Shankar et al. 2007).  Unexpectedly, 
adult transgenic Bright mice are usually males, whereas the conventional Bright knockout 
mice (produced in our laboratory) that survive embryonic lethality are primarily females 
(L. Allred, personal communication).  SLE patients have lower sperm counts and 
decrease sperm motility.  In one study all 35 patients with SLE either suffered from 
teratozoospermia or reduced sperm concentration (oligozoospermia/azoospermia) (Soares 
et al. 2007).  Furthermore, in another study, anti-sperm antibodies associated with anti-
double-stranded DNA (anti-dsDNA) antibodies were found in 42% of lupus patients 
(Reichlin and Haas 1985).  The thymus is another tissue that has been reported to have 
promiscuous gene expression, and recent work has implicated this in T-cell tolerance 
(Derbinski et al. 2001, reviewed in Magalhães et al. 2006).  Currently a model exists in 
which the thymus expresses peripheryl self antigens to facilitate tolerance generation that 
would otherwise be isolated from the immune system.  Aire (autoimmune regulator) is 
mutated in patients with endocrinopathy-candidiasis-ectodermal dystrophy (APECED) 
and is expressed in the thymus and testes (Schaller et al. 2008).  Aire has been shown to 
regulate promiscuous gene expression and is implicated in scheduled apoptosis.  Aire-
deficient mice have a reduction in apoptosis. This appears to be independent of its 
immune function, as there was no significant change in RAG-1-/- background mice.  
There were about half the number of spermatocytes in Aire-/- mice as compared with 
Aire +/- littermates.  The authors proposed that promiscuous gene expression in the testis 
serves as a checkpoint, and that cells with mutated genes would undergo apoptosis.  
Apoptosis is thought to be required for normal spermatogenesis, as mice that overexpress 
anti-apoptotic genes (bcl2 or bclxL) are sterile (Rodreguez et al. 1997 and Furuchi et al. 
1996).  Much can be learned from understanding the regulation of promiscuous gene 
expression, as well as its immunological significance in the testes and thymus. Its 
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regulation during spermatogenesis and immune tolerance will be an interesting but 
arduous task to unravel.  
 
 
 
 
 
 
 
 
Figure 26.  Immunohistochemical localization of Brightlike in murine testes.  
Brightlike antibody stained spermatids and mature spermatozoa more stongly then 
spermatogonia and sertoli cells.    
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Appendix A. Primers 
Name (UniSTS #) Sequence Gene product size 
    
BL_Y197A_F  GAAGTATTTGTACCCAGACGAGTGCGAGACACGGG Brightlike n/a 
BL_Y197A_R  CCCGTGTCTCGCACTCGTCTGGGTACAAATACTTC  
SumoK1mutbF GCCCGAGCCCAGTAAGGAAAGAGGAGAG Brightlike n/a 
SumoK1mutbR CTCTCCTCTTTCCTTACTGGGCTCGGGC   
Bright-F (UniSTS:163480)  CACTGTCTTAGCCGCACAAT Bright 108bp 
Bright-R   TATCCCTGAGCCAGTTACCC     
CD4-F (UniSTS:141282) AGGAGAGGATTAACTCTTGAA CD4 123bp 
CD4-R  CATGCATGTGTGCAACATGCG    
CD8-F (UniSTS:270412) TCCAGCTCCAAACTCCCC CD8 235bp 
CD8-R   TCTGAAGGACTGGCACGAC    
ACTb-FWD TACGAGGGCTATGCTCTC Beta-Actin ~600 
ACTb-REV CGCAGCTCAGTAACAGTC   
Bright-Fwd   ACACGCTGAGGGAGATAGGCATTT Bright  
Bright-Rev   TCCTCTTTCTTGATCTTGGGCGCT  876bp 
5’Tubulin CAGGCTGGTCAATGTGGCAACCAGATCGGT Tubulin  
3’Tubulin GGCGCCCCTCTGTGTAGTGGCCTTTGGCCCA   
HsBlike_001_S Hs 22  GACTGCGCCTGGAAGCTGTCAT human BL 1168nt 
HsBlike_002_AS Hs 20  GCAATGGGGCTGGGACTCTT   
HsBlike_003_S Hs 19  ATGGAGGCCCTGCAGAAGC  full length 
HsBlike_004_AS Hs 17  GGACCTCTCAGGGCAAG   
HsBlike_005_S Hs 18  CCCCAAGAGGAAGGAATT  782 nt 
HsBlike_006_AS Hs 16  TGATACTGCTGATGCC   
HsBlike_007_S Hs 17  CCCATCATGGCGAAGCA  199 nt  
HsBlike_008_AS Hs 17  TCTCGCACTCGTACGGG   
BL-X4/5-F2 CGACGCAGTAAAGAAAGAGGAGA murine BL 314/224 
BL-X7-R2 TTGGCGTCGAGCAAAGAGGATA   
BL-X4-F1 ACCCAGGGTTCTGCTTCTGGTTA murine BL 417/327 
BL-X7-R1 TGTAGAGGGTAGAGGTGGAGGATT   
ChIP-F CTAGATCCACATGTATGATTT S107  
ChIP-R GTCTTTCAGACAATAGATTGG   
V1-F GRATCCAGTGTGAGGTGAAGC S107  
Cu-R GAGCTTCCCATCCTTTAGCCA   
BL5UTR AGGGGGACTGCGCCTGGAAGCTGTAAT BL  
BL3UTR TCCCAGAGTGGGCGTCACATCCTGA   
BL-FL-F ATGGAGGCCCTGCAGAGGCAG BL 1230/1140 
BL-FL-R TCAGGGCAAGGTACTGGAGGGG   
BRL-EXON6-F TCCCACCCAGGGTTCTGCTTCT BL  
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BRL-EXON6-R ACTGCTGATGCCACTGCCTG   
BLRT-FI-D C/TCCC/TA/GAA/GAGGAAA/GGAA/GTT ARID  
BLRT-FI-NOND CCCCAAGAGGAAGGAGTT BL  
BLRT-R1-NOND TACAAATACTTCATGTAC BL  
BLRT-R1-D TANAG/AG/ATANTTCTAC/TTAA/G ARID  
BLRT-R2-NOND GTTGATACTGCTGATGCC BL  
BLRT-R2-D TCCACNGACATC/TA/GATC/TC ARID  
BLRT-F2-D CCC/TATC/TATGGCNAAG/ACAG/ACA ARID  
BLRT-F2-NOND CCCATCATGGCCAAACA BL  
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